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SUMMARY
Major advances in the treatment of leukaemia and lymphoma in 
the 1960s and 70s led to the euphoric belief that solid tumours 
would also yield to cytotoxic chemotherapy. Unfortunately this 
promise has remained largely unfulfilled. Many reasons are 
cited for this therapeutic failure, but it is generally accepted 
that drug resistance, either arising *de novo* or aquired, is a 
major factor in this problem. The work detailed in this thesis 
looks at some possible methods of overcoming so-called 
pharmacological resistance* i.e. drug resistance based on an 
inability to deliver enough active drug to it*s site of action.
The anthracycline class of anti-tumour agents form one of the 
cornerstones of modern chemotherapy of both leukaemias and 
lymphomas as well as solid tumours. Since the introduction of 
these drugs many attempts ( mainly through analogue 
development ) have been made to improve their therapeutic 
efficacy by increasing lipophilicity and thereby enhancing drug 
penetration into tumour. The data shown in chapter 2, using the 
in-vitro human multicellular tumour spheroid model, demonstrates 
the penetration limitation of anthracycline. In the in-vivo 
situation the intravenously administered cytotoxic drug has to 
traverse many penetration barriers before reaching the tumour 
micro-environment, this will exacerbate any penetration problems
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encountered in the in-vitro test system which one could regard 
as the best possible scenario for penetration ( since the 
cytotoxic is present in excess in the medium surrounding the 
tumour nodule ). The data generated using other drugs also 
demonstrates that this is not a universal property of 
cytotoxics. Since the anthracyclines are already amongst the 
most efficacious cytotoxics it is possible that overcoming this 
problem may further improve on their therapeutic benefits.
Theoretically the problem of penetration may be overcome by a 
variety of methods. The work presented here concentrates on two 
possibilities; the first being delivery of a penetration 
enhancing agent together with the cytotoxic, the second is the 
targeting ( or selective concentration ) of drug to tumour 
tissue thereby achieving local concentration of cytotoxic not 
attainable by simple intravenous administration. If one assumes 
that penetration of drug into tumour is on the whole by passive 
diffusion, then a higher local concentration would lead to 
increased penetration into a nodule of tumour.
The data in chapter 3 looks specifically at the use of 
surfactants as penetration enhancing agents. The tested 
surfactants proved to have unexpected toxicities when given 
intravenously to rodents, and the simplistic approach of co­
administration seemed to have no benefit. This theme is further 
developed in chapter 4, when the same surfactants are used to 
make vesicular formulations containing anthracyclines which are
used as a drug delivery vehicle. This approach may be an 
improvement in that the vesicle nature and composition may be 
manipulated to encourage a degree of tumour targeting. The 
results of this approach are a change in the pharmacokinetic 
behaviour of the anthracycline with some slow-release 
characteristics and some success in targeting. However, the in- 
vivo activity against a rodent tumour model is disappointing, 
probably because of bonding of the anthracycline to some 
component of the vesicle causing inactivation of the cytotoxic.
Historically, surfactant vesicles are at an early stage of 
development, but show some promise. Liposomes (which are lipid 
based vesicles ) have a much longer history of investigation 
over the last 20 years, with various well established 
pharmaceutical applications. It is therefore not surprising 
that the results in chapter 5 dealing with a liposomal form of 
anthracycline show changes in pharmacokinetics, with a six fold 
increase in tumour AUC , which translates into enhanced anti- 
tumour activity in an in-vivo tumour model. This particular 
formulation is currently in early clinical trials in various 
centres.
A related method of drug targeting is the use of macro- 
molecular carriers to which drug can be attached, with 
subsequent release at the site of action. In chapter 6 the use 
of N-(2-hydroxypropyl)methacrylamide [HPMA] co-polymer bound 
anthracycline is explored. HPMA was originally developed as a
23
plasma expander, and is both non-toxic and non-immunogenic• 
This biodegradable substance is composed of a monomeric backbone 
with multiple carbon based side chains which lend themselves to 
chemical derivatisation. In addition, bonding of drug to the 
polymer can be achieved in such a way that only lysosomal 
enzymes can release drug from polymer. This has the dual 
purpose of targeting together with selective concentration 
within the cells and tissues with high endocytic activity such 
as certain tumour types. The results using this system are a 
high level of targeting with a marked increase in therapeutic 
efficacy, the pharmacokinetic results also imply an enhanced 
therapeutic ratio for this preparation. These results together 
with other pre-clinical data have led to a commit ment to 
develop this for human studies.
The novel intra-lysosomal route taken by the HPMA 
anthracycline copolymers raises the possibility that this may be 
a way of avoiding the classical multi-drug resistance phenotype 
of some experimental and human tumours, characterised by 
resistance to a number of ’natural product1 cytotoxic agents, 
together with the presence of a 170 Kilodalton transmembrane 
peptide known as P-glycoprotein. This protein acts as an 
energy-dependent efflux pump, that reduces intracellular drug 
accumulation, thereby conferring resistance to many different 
drugs. This hypothesis is tested in chapter 7 using a naturally 
sensitive parent and resistant daughter pair of human ovarian
24
cancer cell lines. The resistant line was derived by serial 
passage in ever increasing drug concentrations and has been 
shown to express an abundance of P-glycoprotein by other workers 
using the same cell lines. When exposed to free or HPMA
copolymer bound anthracycline these particular cell lines show 
only minor changes in the pattern or degree of response. This
could be explained by the very high levels of P-glycoprotein,
which may be far in excess of the amount encountered in-vivo, or 
by as yet undiscovered resistance mechanisms independent of this 
pump mechanism.
In conclusion, the work in this thesis shows that
anthracyclines are limited by poor tumour penetration and that 
methods exist to improve on this situation, the most promising 
being the use of liposomes and H P M A  copolymers.
25
CHAPTER 1
GENERAL INTRODUCTION
The 1960s and 70s brought major improvements in the treatment 
of the leukaemias and lymphomas. The advances made in these 
previously fatal illnesses were prompted by the introduction of 
new drugs; and with this a better understanding of the mechanism 
of action of existing drugs, allowing for logical drug 
combinations to be introduced. These changes resulted in major 
improvements in response rates and survival of patients with 
these malignancies. It appeared that the lessons from these 
disease states could be directly applied to the treatment of 
solid tumours, with similar results. Unfortunately, this promise 
has not been fulfilled. In the last decade few new cytotoxic 
drugs have become available in the clinic ( other than analogues 
of existing drugs ), and the widespread application of multi­
agent treatment has failed to significantly alter the survival 
rates for the majority of patients with advanced forms of 
common solid tumours, especially lung, breast and colon cancers 
(DeVita, Heilman & Rosenberg, 1989 ).
In this rather depressing situation it is even more important 
that we look carefully at existing cytotoxic agents in a 
critical way. Therapeutic failure may be as important as success 
insofar as our understanding of the basic biology of cancer. 
Thus it is important that we strive to understand the mechanisms
26
of resistance either de novo or aquired, as applied to single 
cells or to intact tumours within the host. In attempting to 
explain these phenomena it is likely that we may 'stumble' upon 
mechanisms or strategies by which existing therapies can be 
improved, or by which the emergence of resistance may be 
circumvented.
The purpose of this short introduction is to highlight two
( some others are given in Table 1 ) of the fundamental problems
facing any cytotoxic drug. These are:-
1. Is it possible to achieve a sufficiently high 
concentration of drug in the region of the tumour, without
causing unacceptable toxicities in other tissues?
2. Can the drug in the region of the tumour then diffuse 
through the tumour substance and into the neoplastic cells, with 
resultant death of these cells?
The first of these questions can only be answered by the use 
of in-vivo model systems, with all the attendant expense and 
complexity that these demand. It is clear from experiments using 
material derived from some types of human tumours that solid 
tumours are not inherently insensitive to all forms of currently 
available treatment. Therapeutic failure results in at least 
some cases from an inability to achieve therapeutically
effective drug levels at the tumour ( Stallard et al, 1989 ). It
27
Table 1
Potential problems or barriers to drug targeting
Tumour factors
Cellular heterogeneity
Phenotypic changes with time or metastases 
Membrane transport of drug
Host factors
Plasma protein binding
Degradation by intravascular enzyme systems
Reticulo-endothelial system
Immune system
Vascular egress
Diffusion to site of action
Intracellular drug transport
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is possible to measure the drug concentration within tumours, 
and then to design and test strategies to improve 1 drug 
delivery1. It is also possible to measure drug concentrations in 
certain organs of toxicity for various drugs, and then to 
attempt to divert drug away from these organs and to enhance 
drug deposition in the tumour, so called 'drug targeting1. 
Specific methods to improve drug delivery or targeting are 
discussed in more detail in subsequent chapters.
The second question is more difficult to explore in-vivo 
because of inter-individual differences in pharmacokinetics of 
drugs, and because methods of bracking1 the destination and 
intracellular fate of most cytotoxics are not available. Hence, 
an in-vitro approach employing the human multicellular tumour 
spheroid ( Sutherland, McCredie & Inch, 1971 ) system has been 
used in some of the work within this thesis in an attempt to 
identify drugs for which tumour penetration is a problem, and to 
examine ways of modifying penetration. Details of the 
development and use of this system are presented in chapter 2.
Both of these limitations could theoretically be overcome by 
a system of drug delivery or targeting, since increasing the 
local concentration of drug in the vicinity of the tumour should 
facilitate diffusion of drug into the tumour ( assuming that 
this is generally a passive process ). It is therefore worth 
reviewing some of the criteria which an ideal drug targeting 
system should fulfil, and some of the potential obstacles.
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THE TARGET
The target must be expressed by all tumour cells since even 
small numbers of remaining cells could cause recurrence. Since 
tumours are composed of a multitude of phenotypically distinct 
cells, and since not all tumours are alike, even metastases 
within the same host are distinct ( Poste et al, 1982 ); it is 
unlikely that any one molecule will be the target. There are as 
yet few known unique differences between tumour cells and 
normal cells, but many quantitative differences exist which 
could be exploited ( Hawkey et al, 1986 ). Furthermore, the 
cellular phenotypes which make up the tumour are not static, 
some sub-populations die as a result of selective pressure from 
the host or therapy, and are replaced by cells resistant to the 
selection process ( Welch & Tomasovic, 1985 ). If the degree of 
heterogeneity is small enough, then the new sub-populations may 
still express the target, but if there is wide divergence the 
targeting strategy may fail. If it were possible to identify 
the molecular characteristics which define the malignant 
cellular phenotype, then a targeting system to some aspect of 
this should be possible. The closest candidates for this role so 
far are the oncogenes and their products ( Bishop, 1987 ); but 
as yet no specific ( and accessible ) target has been defined, 
with many if not all of the oncogene products having pivotal 
roles in the regulation of proliferation and differentiation of 
normal cells. Some of the more promising potential candidates
I
I
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for drug targets are given in table 2.
Rather than consider the biochemical differences between cell 
types, it may be possible to define functional attributes of 
tumours which lend themselves to targeting. The tumour 
vasculature is derived from the host in response to angiogenic 
factors released by the tumour ( Jain, 1988 ). Microscopically 
this vasculature is rather abnormal, with dilated and tortuous 
vessels which may be partially lined by tumour cells ( Gullino, 
1975 ). These vessels also show ultrastructural anomalies with 
wide interendothelial junctions, fenestrae and discontinuous 
basal lamina ( Jain, 1987 ). Thus the defective capillary 
networks in some tumours ( Warren, 1970 ) may allow a degree of 
targeting through selective leakiness of the vasculature. Some 
tumour types also exhibit an increased endocytic rate ( Sehested 
et al, 1987 ), which may allow targeting via this route. An 
alternative approach may be to target the drug to a particular 
organ or tissue in which the tumour resides, an example would be 
the reticulo-enothelial trapping ( and hence hepato-splenic 
targeting ), of most forms of liposomes ( Kaye & Richardson, 
1979 ).
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Table 2
Potential cellular targets for drug targeting to tumour cells
Oncogenes 
Oncogene products 
Cell surface:-
Tumour cell antigens
Adhesion or attachment molecules
Membrane receptors e.g. growth factor receptors
32
THE DELIVERY SYSTEM
It is possible to define certain requirements of a drug 
delivery system which would be necessary in order to overcome 
the barriers to drug targeting as listed in table 1. Table 3 
outlines some of these basic properties.
The apparently simple concept of drug delivery is in reality 
a very complex problem. The problems for cytotoxic delivery are 
generally worse than for other drugs such as antibiotics, 
because most cytotoxics have major ( if not life threatening ) 
toxicities which may be exacerbated if drug is inadvertently 
delivered to an inappropriate site. Additionally, most 
cytotoxics are highly reactive molecules, which presents 
problems of drug bonding to the carrier, or of inactivation of 
drug. Even getting the drug to the tumour does not guarantee 
that the drug will be effective. The drug must then be 
transported into the cell as an active form or as a prodrug to 
be activated inside the cell.
The host immune system also represents a barrier to drug 
delivery. The delivery system itself may cause an immune 
response, with the reticulo-endothelial system sequestering the 
drug before it has a chance to reach the target.
Finally, the delivery system must be simple enough in 
chemical structure to allow for large scale production of 
material of suitable purity at reasonable cost.
33
Table 3
Requirements for a drug delivery system
Ability to incorporate a broad spectrum of drugs 
Maintenance of activity of bound drugs 
Protect drug from premature degradation 
Non-immunogenic 
Recognition of target
Delivery of therapeutic drug concentrations
Release of active drug at target
Biodegradable
Biologically inert
Large scale production feasible
Cost-effective
/34
PURPOSE OF THE THESIS
This thesis examines the problems of drug penetration and 
drug delivery for one class of cytotoxic agents, namely the 
anthracyclines. It examines some approaches which have been 
around for many years e.g. liposomes; and others which are 
entirely novel such as polymeric carriers and surfactant 
vesicles. Each chapter is prefaced by a more detailed review of 
the literature pertinent to the particular approach employed.
The hypothesis to be tested is that the efficacy ( 
therapeutic index ) of anthracyclines can be significantly 
improved by the use of synthetic drug carriers; whose role may 
be to enhance drug penetration, alter host pharmacokinetics or 
promote selective endocytic tumour uptake.
/
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CHAPTER 2
STUDIES USING THE HUMAN MULTICELLULAR TUMOUR SPHEROID MODEL
Multicellular tumour spheroids were first described by 
Sutherland, McCredie & Inch (1971). They are composed of tumour 
cells growing in a three dimensional spherical colony, and 
consist of an outer, fast growing cell layer, an intermediate 
cell layer with few proliferative cells, and a central region 
mainly containing degenerative cells (Sutherland et al, 1981). 
This 3-dimensional structure simulates the growth and 
microenvironmental conditions of malignant tumours in vivo 
(Sutherland, 1986). Thomlinson and Gray (1955) and Tannock 
(1968) showed that only tumour cells near capillaries were 
proliferative and that cells at a distance of about 100-200 um 
degenerated. Penetrating vessels and capillaries were surrounded 
by thin cords of viable cells. These two studies were carried 
out in tumours with a nodular appearance. This has given rise to 
the term "tumour nodule”, describing a capillary with its 
surrounding layer of viable cells and an outer layer of necrotic 
cells. It may also be used for a peripheral network of 
capillaries surrounding a cell "spheroid” that may contain a 
central area of necrosis (Folkman & Greenspan, 1975). The latter 
pattern is almost identical with that seen in cultured 
multicellular tumour spheroids. This spatial arrangement leads
I
I
36
to diffusion gradients for nutrients into the tumour nodule 
which can be modelled in vitro by spheroids; oxygen being one of 
the most intensively investigated of such nutrients (Sutherland,
1986).
Spheroids have been used in a variety of research areas as an 
in-vitro tumour model system of intermediate complexity between 
standard monolayer cultures and tumours in-vivo. In particular, 
the similarity between spheroids and the avascular stage of 
micro-metastases has been emphasised (West, Weichselbaum & 
Little, 1980).
Spheroids are useful for drug cytotoxicity tests because the 
penetration barriers which exist in poorly vascularised parts of 
solid tumours (Goldacre & Sylven, 1962) can in part be 
simulated. The spheroids also contain extracellular matrix 
(Nederman et al, 1984) which may have an important influence on 
drug penetration both in spheroids (Nederman, Carlsson & Kuoppa, 
1988), and in tumours (Jain, 1987). In addition, heterogeneity 
in other microenvironmental factors such as cell cycle growth 
phase can be demonstrated in spheroids and solid tumours in-vivo 
(Sutherland, 1986). Theoretically spheroids may provide a more 
sensitive model than monolayer systems for in-vitro cytotoxicity 
studies. However they present more technical difficulties, and 
such a conclusion would therefore have major practical 
implications. Thus it is important to examine in detail the 
differences in cytotoxicity data for individual drugs when the
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same cell line is tested using both spheroid and monolayer 
systems.
Relative drug resistance in spheroids compared to the same 
cells in monolayer cultures has been demonstrated for many 
cytotoxics including m-AMSA (Wilson, Whitmore & Hill, 1981), 
methotrexate (West, Weichselbaum & Little, 1980), bleomycin 
(Toburen, 1981), vincristine ( Wibe & Oftebro, 1981), 
vinblastine (Nederman, 1984; Nederman & Carlsson, 1984) and 
adriamycin (Sutherland et al, 1979; Durand, 1981; Erlichmann & 
Vidgen, 1984). In most cases this resistance is mainly based on 
poor drug penetration as shown by direct studies such as 
fluorescence, autoradiography or flow cytometry. However, 
microenvironmental factors such as oxygenation and cell cycle 
(Kwok & Twentyman, 1985), or pH changes (Kohn & Ewig, 1976) may 
also have a role in some cases (Sutherland et al, 1979). The 
only exception reported was 5-fluorouracil which seemed to 
penetrate efficiently at least through glioma spheroids 
(Nederman & Carlsson, 1984).
In this chapter are described experiments carried out to 
study the relative response to a variety of cytotoxic drugs of 
L-DAN human tumour cells treated either as multicellular 
spheroids or as monolayer cultures. The purpose of this being to 
establish which anti-tumour agents, if any, are subject to a 
’penetration barrier1, as judged by the spheroid/monolayer 
comparison.
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MATERIALS AND METHODS 
CELL LINE
L-DAN is a human non-small cell lung cancer line derived from 
a primary biopsy from one of our own patients (Merry et al,
1987). The cells are maintained in growth medium consisting of a 
mixture of equal volumes of Ham’s F10 and Dulbecco's Modified 
Eagle*s Medium supplemented with 10% bovine foetal calf serum 
and with a gas phase of 2% CC^. The plating efficiency of this 
cell line is of the order of 15-20%.
DRUGS
The drugs used in this study were adriamycin (ADR, Farmitalia 
Carlo Erba Ltd, Barnet, Herts, UK), vincristine (VINC, trade 
name Oncovin, Eli Lilly and Co Ltd, Basingstoke, UK), 
methotrexate (MTX, Lederle Laboratories, Gosport, Hampshire, 
UK), 5-fluorouracil (5-FU, Roche Products Ltd, Welwyn Garden 
City, UK) and cisplatin ( Lederle Laboratories, Gosport, 
Hampshire, UK). In each case the drugs were solubilised 
according to the manufacturer’s instructions and diluted with 
growth medium to the desired final concentrations on the day of 
the experiment. The final solutions should all be stable under 
these conditions (Bosanquet, 1989), although this was not 
formally tested.
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MONOLAYER CYTOTOXICITY ASSAY
o
L-DAN cells were grown as monolayers in 25 cm flasks 
(Falcon) in growth medium. Three days after inoculation into 
flasks, when the cells were in exponential growth phase, they 
were exposed to drug diluted to the appropriate concentration in 
culture medium for 1 hour at 37®C in a 2% CO£ incubator. Drug 
containing medium was then removed and the monolayers washed 
twice with cold phosphate buffered saline (PBS = Dulbecco's A). 
A single cell suspension was prepared using 0.25% trypsin in PBS 
and lmmol/LEthylene-diamine-tetra-acetic acid (EDTA). Cells were 
inspected microscopically to ensure a monodispersed population 
and counted using a model ZB Coulter counter (Coulter
Electronics Ltd, Luton, UK). The cells were then diluted
appropriately in growth medium and plated in 50mm Petri dishes 
(Nunc, Gibco, BRL, UK) at various dilutions in replicates of 12 
for controls and 9 for drug treated cells.
The dishes were incubated for 14 days at 37^C with 2% C0£ and 
then removed, fixed with methanol for 10 minutes and stained 
with 0.5% dilution of Crystal Violet (BDH Chemicals, Poole, UK) 
for 20 minutes. Colonies of > 50 cells which were visible by 
naked eye were counted manually, and survival in drug-treated 
dishes expressed as a fraction relative to control survival. A 
value for log survival (log S) was also derived by the
equation:-
Log S = log (colonies treated/colonies untreated)
/AO
SPHEROID CULTURE
Initiation of spheroids from monolayer L-DAN was performed by 
an adaptation of the method of Sutherland, McCredie & Inch 
(1971). Briefly, 10^ cells were seeded into 200 ml of growth 
medium in glass spinner flasks (Techne, Cambridge, UK). The 
medium in addition contained 2.5 ug/ml of amphotericin, 100 
IU/ml penicillin and 100 ug/ml streptomycin (Gibco Ltd, Paisley, 
Scotland) to reduce culture infections which are more common 
than in monolayer systems because of the repeated manipulations 
required in spheroid culture. Control experiments showed that 
the addition of these antibiotics did not affect parameters of 
growth in these spheroids (data not shown). The suspensions were 
maintained at 37^C in a 5% CO2 incubator and rotated at 40 
revolutions per minute using a magnetic stirring device (Techne, 
Cambridge, UK). Aggregation of cells occurred in approximately 5 
days and spheroids reached a diameter of approximately 200 um by 
day 8-9, at which time they were used for drug cytotoxicity 
experiments. In general, the spheroids grew with Gompertzian 
kinetics.
SPHEROID CYTOTOXICITY ASSAYS
10 ml aliquots of medium and spheroids were transferred into
sterile plastic universal tubes for treatment of intact
spheroids. The spheroids were allowed to settle by gravity and
Al
the medium discarded and replaced by 10 ml of fresh medium 
containing the test drug at appropriate final concentration. The 
samples were incubated at 37^C for one hour with intermittent 
agitation by hand to ensure even exposure of all spheroids to 
drug. After incubation the spheroids were allowed to settle, the 
drug containing medium was removed and the spheroids rinsed 
twice in cold PBS. Each rinse lasting 3 minutes in an attempt to 
eliminate the theoretical possibility of later diffusion of drug 
from a ’pool* trapped in the central necrotic zone of the 
spheroid. The spheroids were then resuspended in fresh medium 
and individual spheroids transferred by Pasteur pipette into 
agar based 24 well plates (Corning USA, supplied by J.Bibby 
science products Ltd, Stone, Staffs, UK) with 0.5 ml of medium 
in each well. Spheroids were then selected by eye with a
tight size distribution (i.e. all spheroids between 150-250 um 
in diameter), so that growth curves for groups of spheroids 
should not be influenced by a wide variety of initial sizes.
Subsequent growth of the spheroids was measured using an 
inverted microscope coupled to a microcomputer based image 
analyser (Analytical systems model 40-10) which gives a cross- 
sectional measure of each spheroid, which can then be converted 
to volume assuming spherical geometry. Measurements were made at 
least twice-weekly, and the wells were topped up with 0.5 ml of 
fresh medium every 7 days. Between 20-24 spheroids/treatment 
group and control were utilised for each experiment. 2-4 
experiments were performed for each drug treatment. Growth delay
i4 2
was determined by measuring the time required for the spheroid 
volume to increase by a factor of ten for control and drug- 
treated spheroids. The growth delay was defined as the 
difference in time between drug-treated and control spheroids to 
reach this 10-fold increase in volume. We chose 10-fold 
increases in volume because initial studies had shown that the 
growth curves at this point were generally parallel to each 
other. Very few spheroids failed to regrow following treatment, 
so that no 'cure correction* was necessary to the growth data.
Clonogenic survival may be deduced from tumour regrowth data 
by (back-)extrapolation of regrowth curves to zero dose. These 
deductions have been attempted in-vivo but are complicated by 
possible immunological responses, the limited proliferation 
potential of so called 'doomed cells' and the practical 
difficulty of obtaining accurate measurements of the regrowing 
tumour (Wheldon, 1980). In the absence of most of these effects 
for the in-vitro situation pertaining to multicellular tumour 
spheroids, it seems reasonable to interpret the spheroid 
responses as being mainly due to sterilisation of clonogenic 
cells. Thus back-extrapolation of the regrowth curves has been 
attempted when the curves become parallel with control curves 
( see figure 2). By this method a 'surviving fraction* of 
clonogenic cells can be derived and directly compared with the 
results of the monolayer clonogenic assay (Wheldon et al, 1985).
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'BACK-EXTRAPOLATION’ 
LOG VOLUME
Control
Treated
Log S = Log V_ — Log V,
Figure Is Illustration of method of back-extrapolation of
spheroid regrowth curves.
/RESULTS
CISPLATIN
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Figure 2; Structure of cisplatin. MW=300
Cisplatin is thought to exert its cytotoxic action by
inhibition of DNA replication which results from complex co­
ordination to bases in DNA, mainly at the N7 position of guanine
I45
and adenine nucleotides (Roberts, 1986). There is no unique
administration protocol for this inorganic compound, and its
pharmacokinetics are dependent on both route and schedule of
administration (Gouyette et al, 1986). A commonly used schedule
o
in this country is lOOmg/m over 6 hours by intravenous infusion 
with saline diuresis. This schedule results in peak plasma 
levels of free platinum (thought to be the active form) in the 
region of 5-15 ug/ml (Ribaud et al, 1981). Free platinum half- 
lives of 30 minutes have been reported for bolus (Himmelstein et 
al, 1981) and infusion routes (Reece et al, 1985).
Figure 3 shows a dose-response curve for cisplatin against 
exponential phase L-DAN cells. The results are expressed as 
percentage of control growth versus cisplatin concentration. 
Each point is the mean of two experiments +/- standard error. 
The curve was drawn by eye as the best fit of observed data.
Figure 4 shows a representative experiment from a series of 
three in which L-DAN spheroids were exposed to cisplatin for one 
hour. Each set of symbols shows the median log volume from 20-24 
individual spheroid measurements and the 95* confidence 
intervals about this median value. In the interest of clarity 
the figure does not show all of the tested doses of cisplatin, 
but these are included in table 4. Repitition of this experiment 
with spheroids of a smaller starting volume yielded similar 
results, as shown in figure 5. The growth delay data derived 
from both the * small* and * large* spheroids are shown in table 
4.
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Figure 3: Dose-survival curve for L-Dan cells exposed to
cisplatin in monolayer cultures
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Figure 4: Regrowth curves of 'large' L-Dan spheroids following
exposure to cisplatin. KEY: Control® open squares. 10 ug/ml®
filled triangles, 20 ug/ml® open cirles, 40 ug/ml® stars.
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TABLE 4
DOSE(ug/ml) GROWTH DELAY (days)
SMALL LARGE
0 0 0
5 0.9 0
10 4.4 1.6
20 11.2 9.8
30 14.7 13.2
40 ND 27.2
ND=not done.
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Figure 5: Regrowth curves of ’small* L-Dan spheroids following
exposure to cisplatin. KEY: Control- open squares, 10 ug/ml=
filled triangles, 20 ug/ml* open cirles, AO ug/ml* stars.
D
A
Y
S
The comparative log S versus dose plots are shown in figure 6. 
Back-extrapolation of the spheroid regrowth curves was only 
possible up to a dose of 20 ug/ml because at higher doses the 
curves failed to return to parallel with the control curve (this 
is a violation of one of the assumptions implicit in this 
model).
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Figure 6: Log S versus dose of cisplatin plot for L-Dan 
spheroids and monolayer* KEY: Monolayers= open squares, 
spheroids= filled circles.
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RESULTS
5-FLUOROURACIL
H
N
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Figure 7; structure of 5-Fluorouracil. MW*130
5-Fluorouracil (5-FU) is a potent pyrimidine anti-metabolite 
which blocks thymidylate (and thereby DNA) synthesis and 
interferes with RNA synthesis, leading to numerous consequences 
for the affected cell (Mandel, Klubes & Fernandes, 1978, Pinedo 
& Peters, 1988). The main action of the drug is in the S-phase 
of the cell cycle, and the drug is most toxic to proliferating 
cells (Tannock, 1978). 5-FU is most commonly given as IV bolus
/53
, o
injections at doses ranging from 300-600mg/m , and exhibits 
nonlinear pharmacokinetics in humans (Collins, Dedrick & King, 
1980). These IV doses give rise to peak plasma levels of 5-FU in 
the region of 60ug/ml (MacMillan, Wolberg & Welling, 1978).
Figure 8 shows a dose response curve for 5-FU against 
exponential phase L-DAN cells in monolayer cultures. The results 
are expressed as percentage of control growth versus 5- 
fluorouracil concentration. Each point is the mean of two 
experiments +/- standard errors. The curve was drawn by eye as 
the best fit to the data. The derived values of log S are given 
in table 5.
Figure 9 shows representative regrowth curves of L-DAN 
spheroids exposed to the stated concentrations of 5-FU. In the 
interest of clarity only a limited dose range is illustrated, 
but log S values for all concentrations tested are given in 
table 5. Each set of symbols shows the median log volume from 
20-24 individual spheroid measurements and the 95% confidence 
intervals about this median value. Since the regrowth curves are 
parallel with the control curve back-extrapolation has been 
performed giving the results shown in table 5 and plotted in 
figure 10.
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Figure 8: Dose-survival curve for L-Dan cells exposed to 5- 
fluorouracil in monolayer cultures
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Figure 9: Regrowth curves of L-Dan spheroids following exposure
to 5-fluorouracil. KEY: Control= open squares, 200ug/ml= filled
triangles, 400ug/ml= open circles, 600ug/ml= stars.
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TABLE 5
DOSE LOG S
(ug/ml) Monolayer Spheroids
10 -0.002 0
100 -0.35 -0.6
200 -0.46 -1.07
300 -0.43 -0.98
400 -0.5 -1.2
600 -0.5 -1.0
700 -0.57 -1.35
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Figure 10: Log S versus dose of 5-fluorouracil plot for L-Dan 
spheroids and monolayers, KEY: Monolayers= open squares, 
spheroids^ filled circles.
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RESULTS
ADRIAMYCIN
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Figure 11; Structure of Adriamycin. MW=580
Adriamycin is an anthracycline antibiotic with a wide 
spectrum of clinical activity in both solid tumours and 
haematological malignancies. It is probably the single most 
active agent available at present.
Despite the clinical importance of this group of drugs and
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major research efforts, the mechanism of action of the 
anthracyclines is still uncertain. Most would support a nuclear 
site of action, with DNA as the prime target (Capranico et al, 
1989), and this is supported by cytofluorescent localisation 
studies ( Egorin et al, 1974). The possible mechanisms of DNA 
damage include
1) production of free radicals (Sinha & Gregory, 1981) though 
this appears not to be of importance in-vivo (Potmesil, Israel & 
Silber, 1984).
2) direct intercalation of DNA through the aglycone moiety 
(Pigram, Fuller & Hamilton, 1972), which can be demonstrated by 
a variety of techniques including nuclear magnetic resonance 
(Feigon et al, 1984).
3) binding through ternary complexes of iron, adriamycin and DNA 
(Eliot, Gianni & Myers, 1983).
4) stabilisation of topoisomerase II-DNA complex in an open 
(cleaved) conformation of DNA (Pommier et al, 1985).
The situation is made more complex by the ability of 
anthracyclines to inhibit RNA synthesis (Kriebardis, Meng & 
Aktipis, 1984); to damage nuclear membranes (Mimnaugh et al, 
1985); and cell membranes (Goormaghtigh & Ruysschaert, 1984. 
Hickman, Chachwala & Thompson, 1985) leading to alterations in 
ion permeability (Santone et al, 1986). Some would even claim 
that they can be cytotoxic without entering the cell (Tritton & 
Yee, 1982. Rogers, Carr & Tokes, 1983).
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The dose schedule in most common use is 40-60 mg/m by IV 
injection every 3 weeks. This results in plasma levels of the 
order of 1-2 ug/ml (Kerr et al, 1986. Benjamin, Riggs & Bachur, 
1977).
Figure 12 shows a dose response curve for adriamycin against 
exponential phase L-DAN cells in monolayer culture. The results 
are expressed as percentage of control growth versus adriamycin 
concentration. Each point is the mean of 2-3 experiments +/- 
standard errors. The curve was drawn by eye as the best fit to 
the data. Corresponding values for log S are given in table 6.
Figure 13 shows a series of representative regrowth curves 
for L-DAN spheroids after 1 hour exposure to the stated 
concentration of drug. Each set of symbols is the median log 
volume from 20-24 spheroids and the 95% confidence limits about 
this value. Log S values for these curves and all other tested 
concentrations (data not shown) derived by back-extrapolation of 
the curves are given in table 6, and plotted in figure 14.
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Figure 12: Dose survival curve for L-Dan cells exposed to 
adriamycin in monolayer cultures.
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/TABLE 6
Dose
(ug/ml)
0
0.1
0.5
1.0
2.5
5.0
10.0
Monolayer
0
- 0.02
-0.27
-0.54
-1.4
-2.15
-2.44
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Log S
Spheroids
0
-0.0004
ND
-0.15
-0.4
-0.41
-0.43
ND - not done.
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Figure 13: Regrowth curves of L-Dan spheroids following
exposure to adriamycin. KEY: Control= open squares, 10ug/ml=
filled triangles, 2.5ug/ml= open circles, 5ug/ml= stars.
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Figure 14: Log S versus dose of adriamycin plot for L-*Dan 
spheroids and monolayers. KEY: Monolayers= open squares, 
spheroids® filled circles.
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RESULTS
METHOTREXATE
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Figure 15: Structure of methotrexate. MW=472
Methotrexate is believed to produce cytotoxicity by depletion 
of reduced folates which are necessary for the synthesis of 
thymidylate, purines and certain amino acids. Depletion of these 
substrates results from the tight binding inhibition of 
dihydrofolate reductase. Li and Kaminskas (1984) reported a 
linear correlation of DNA strand breaks and cell death in cells 
exposed to methotrexate. They hypothesised that the DNA strand
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breaks were the ultimate cause of cell death, and since the 
strand breaks occurred in mature DNA, they suggested that the 
breaks were the result of ineffective repair mechanisms.
The spectrum of clinical activity of methotrexate is wide. 
The use of the biochemical antidote, 5-formyltetrahydrofolate 
(leucovorin, citrovorum factor), has allowed the use of very 
high doses (Goldman & Matherly, 1985). Doses in clinical usage 
range from 0.5mg to >30g/m , and there is wide inter-individual 
variation in drug handling, emphasising the need for monitoring 
of plasma methotrexate concentrations during high dose treatment 
(Bertino, 1981). Plasma levels greater than O.lumolar (approx 
0.5 ug/ml) would be expected to be cytotoxic. A dose of 100 
mg/m will result in peak plasma levels of around 10 umolar; a 
dose of 1.5 g/m results in a peak of 0.1-1 mmolar (Chabner, 
Donehower & Schilsky, 1981). Figure 16 shows a dose response 
curve for methotrexate (one hour exposure) against exponential 
L-DAN cells. The results are expressed as percentage of control 
growth versus methotrexate concentration. Each point is the mean 
of 3 experiments +/- standard error. The derived values of log S 
are given in table 7.
Figure 17 shows representative regrowth curves of L-DAN 
spheroids exposed for one hour to the stated concentrations of 
methotrexate. Each point shows the median log volume from 20-24 
individual spheroid measurements (the 95% limits are too small 
to plot accurately). Log S values for all the tested drug 
concentrations are given in table 7.
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Figure 16: Dose survival curve for L-Dan cells exposed to 
methotrexate in monolayer cultures
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TABLE 7
Dose Log S
(ug/ml) monolayers spheroids
1 0.12 ND
2 -0.08 ND
3 -0.004 ND
4 -0.1 ND
5 -0.02 -0.23
10 0.04 -0.09
50 -0.07 -0.37
100 -0.01 -0.38
500 -0.08 -0.34
750 0.03 ND
1000 0.03 -0.37
1250 0.004 ND
1500 0.009 ND
1750 0.01 ND
ND - not done.
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Figure 17: Regrowth curves of L-Dan spheroids following
exposure to methotrexate. KEY: Control® open squares, 10ug/ml=
filled triangles, 100ug/ml= open circles, 1000ug/ml= stars.
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Figure 18 shows the comparative log S values for L-DAN 
spheroids and monolayers when exposed to the stated
concentrations of methotrexate for one hour.
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Figure 18: Log S versus dose of methotrexate plot for L-Dan 
spheroids and monolayers, KEY: Monolayers= open squares, 
spheroids® filled circles.
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VINCRISTINE
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Figure 19: Structure of Vincristine MW=922
Vincristine is a member of the vinca alkaloid family of 
cytotoxic drugs. These agents kill cells by disrupting 
microtubular structures by binding to tubulin (Owellen, Owens & 
Donigian, 1972) and preventing its polymerisation (Owellen et 
al, 1976). This results in defective mitotic spindle formation, 
impaired cellular motility (Mareel & DeMets, 1984) and perturbed 
intracellular transport systems (Ruzzier et al, 1984. Bennett, 
Parsons & Carlet, 1984).
I
I
K H
o ooo in
H1M0H9 10H1N00 %
Figure 20: Dose survival curve for L-Dan cells exposed to 
vincristine in monolayer culture.
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The standard clinical dosage of vincristine in adult practice 
is 1.4 mg/m*6 intravenously every 3 weeks. This dosage results in 
peak plasma concentrations of around 100 nmol/L = 90 ng/ml 
(Owellen, Root & Hains, 1977). Vincristine has a large volume of 
distribution and a long biological half-life indicating avid 
tissue binding and slow drug release from the body tissues 
(Sethi et al, 1981).
Figure 20 shows a dose response curve for vincristine against 
exponential L-DAN cells in monolayer culture. The results are 
expressed as a percentage of control growth versus vincristine 
concentration. Each point is the mean of 3-9 experiments +/- 
standard error (more replicates were required at some 
concentrations because of wide variability between 
experiments). The derived values of log S are given in table 8.
Figure 21 shows representative regrowth curves of L-DAN 
spheroids exposed for one hour to the stated concentrations of 
vincristine. Each set of symbols is the median of 20-24 
individual spheroid measurements and the 95% confidence limits 
about that value. Log S values for all the tested drug 
concentrations are given in table 8.
Figure 22 shows the comparative log S values for L-DAN 
spheroids and monolayers when exposed for one hour to the stated 
vincristine concentrations.
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Figure 21: Regrowth curves of L-Dan spheroids following exposure
to vincristine. KEY: Control^ open squares, 10ug/ml= filled
triangles, SOug/ml^ open circles.
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TABLE 8
DOSE Log S
(ug/ml) Monolayer Spheroid
0.25 -0.009 -0.02
0.5 -0.03 -0.07
1.0 0.013 -0.07
2.5 -0.018 -0.24
5.0 -0.04 -0.36
10.0 0.03 -1.3
20.0 0.04 ND
30.0 -0.17 -2.3
40.0 -0.3 ND
50.0 -0.58 -3.33
60.0 -1.3 ND
70.0 -1.9 ND
ND - not done.
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Figure 22: Log S versus dose of vincristine plot for L-Dan 
spheroids and monolayers. KEY: Monolayers= open squares, 
spheroids= filled circles.
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DISCUSSION
This series of experiments confirms and extends the 
observations of other groups that when comparisons of 
cytotoxicity in monolayer or spheroid systems are made, tumour 
cells differ, and that 3 groups can be recognised (Erlichman & 
Vidgen, 1984).
Clearly cisplatin has similar effects in both growth systems 
for this cell line, implying that penetration into the spheroid 
is not a problem for this drug. This is contradictory to data 
generated using proton induced x-ray emission as a measure of 
cisplatin penetration into intraperitoneal nodules of tumour 
(Los et al, 1989), but is compatible with data generated for the 
platinum analoque paraplatin (Durand, 1979). It is possible that 
this apparent contradiction is due to more close 1 packing1 of 
the cells in-vivo, or that the extracellular matrix permeability 
is different in the two cell types.
Methotrexate had little effect in both growth systems, even 
at concentrations only clinically achievable using high dose 
protocols with forced diuresis and leucovorin rescue. In the 
spheroids there is an apparently small growth inhibition at high 
concentrations of methotrexate, but no effect at all in the 
monolayers. If this difference reflected the percentage of 
Cycling* cells in each system, then the exponentially growing 
monolayers should be most sensitive. It seems likely that this
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apparent effect in the spheroids is an artefact of the 
methodology employed. In the spheroids the drug is presented in 
only 10 ml of culture medium, whereas in the monolayer each 
flask of cells is treated with 25 ml of drug containing medium, 
as a result on a cell-for-cell basis the spheroids will suffer 
from a degree of nutrient deprivation at the very high 
concentrations of methotrexate used.
The data on adriamycin are a confirmation of the results of 
other authors, showing relative resistance in the spheroid model 
based on poor drug penetration into the spheroid. This has been 
demonstrated in the same cell line by fluorescent microscopy 
(Kerr et al, 1988), and in V79 Chinese hamster cells by flow 
cytometry (Durand, 1981). Similar penetration problems have been 
demonstrated in-vivo following intraperitoneal administration of 
adriamycin to mice bearing a transplantable ovarian cancer 
(Ozols et al, 1979).
Fluorouracil shows the opposite of the adriamycin data, in 
other words the spheroids appear to be more sensitive than the 
monolayers. As stated in the introduction to this chapter other 
workers have shown that 5-fluorouracil penetrates with ease 
through glioma and thyroid cancer cellular spheroids (Nederman, 
1984). The apparent increased sensitivity of the spheroids is 
therefore surprising, as one would expect equal sensitivity 
rather than enhanced cytotoxicity in the spheroid if drug 
penetration were the only consideration. As the central cells of
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the spheroid are non-cycling one would also expect a degree of 
resistance to a drug with its main action in the S-phase of the 
cycle (Mandel, Klubes & Fernandes, 1978), as has been 
demonstrated for Chinese Hamster V79 multicellualr spheroids by 
Durand (1986). However Tannock (1987) has shown equal 
sensitivity between aerobic and hypoxic cells to fluorouracil 
exposure in two murine tumours, despite the difference in cell 
cycle. A similar situation was found comparing intact with 
disaggregated spheroids for chlorambucil, mitomycin, thiotepa 
and bleomycin (Durand, 1986). One explanation of this finding 
would be the possibility that fluorouracil having found its way 
into the necrotic core of the spheroid has remained there 
through the washes after drug exposure , and has then diffused 
out from this central ’reservoir1 to cause further cytotoxicity. 
Alternatively this may represent an artefact of the system used, 
Twentyman (1980) described a phenomenon of excessive growth 
delay for the amount of cell kill for some drugs in the 
multicellular spheroid system.
Vincristine shows a similar pattern to fluorouracil. In this 
case penetration into the core of the spheroid is probably 
limited. The penetration of vinblastine (which differs from 
vincristine by only one carbonyl group) has been demonstrated to 
be poor (Nederman & Carlsson, 1984) after short duration of 
exposure. Vincristine also has the highest molecular weight of 
all the drugs tested in this series of experiments, which one
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would intuitively expect would be detrimental to tissue 
penetration. It is therefore unlikely that a central Reservoir* 
of drug could form in this case. Both the monolayer and spheroid 
experiments using vincristine were subject to a higher than 
expected inter-experiment error, and this is the reason for the 
higher numbers of replicates. In particular the spheroid 
experiments were difficult to interpret because of changes in 
the shape and configuration of the cell aggregates; some would 
disintegrate after drug exposure, some would degenerate into 
monolayers, others would become large islands of cells rather 
than spheres making measurements of area invalid. Stephens & 
Peacock (1978) noted that when tumours were treated with 
vincristine in-vivo then excised and dissaggregated extensive 
cell lysis had occurred. This effect has not been noted in 
monolayers, and presumably reflects an increased susceptibility 
to damage of relatively hypoxic cells. This could explain our 
data both in terms of the cytotoxicity and the morphological 
changes observed.
These experiments also highlight some of the limitations of 
the multicellular spheroid system. The data presented looks at 
cytotoxicity indirectly as a function of growth delay. The 
validity of this approach is questionable; for irradiation 
studies there does seem to be a correlation between growth delay 
and cell survival (Moore, West & Hendry, 1987), but for 
cytotoxic drugs the situation is less clear with a breakdown in
I
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this correlation at least for some drug classes (Twentyman,
1980. Yuhas, Tarleton & Harman, 1978). Possible alternative end­
points such as disaggregation or outgrowth on plastic also have 
theoretical limitations. In the case of disaggregation with 
trypsin, it appears that the timing of this procedure with 
respect to drug exposure is crucial (Twentyman, 1980). In the 
case of failure of outgrowth or other so-called ^ u r e 1 
experiments, usually very high (and clinically unachievable) 
concentrations of drug are required to come close to this
successful radiobiological technique (Durand, 1975).
Even accepting the limitations of regrowth delay as an end­
point it was difficult to use back-extrapolation in those 
situations when the regrowth curves do not return to parallel 
the controls, or when changes occur in the morphology of the 
cellular aggregates (as was the case with vincristine).
A further limitation, common to most in-vitro systems is that 
the cells are exposed to specified drug concentrations for a
short time. In reality the cells in a tumour would be exposed to
an oscillating drug concentration over a time which is dependant 
on drug handling by the host. Attempts to get round this problem 
have been made by exposing intraperitoneally implanted spheroids 
to intravenously administered drug, but again this approach is 
severely limited by additional immunological reaction to the 
spheroids (Yuhas, Tarleton & Harman, 1978).
In conclusion, adriamycin is the only agent from this 
selected group of drugs for which penetration into the central
/
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region of the sphecid seems to be a limiting consideration. A 
similar conclusion was made from a recent series of elegant 
experiments using fluorescence activated cell sorting 
techniques, followed by clonogenic assay. This study also 
revealed an apparent dissociation between cellular drug levels 
and activity, implicating a major role for the cellular 
microenvironment in modulating drug toxicity (Durand, 1989).
Despite this problem with penetration, the anthracyclines are 
clinically the most active of cytotoxic agents. It is
therefore logical to attempt to improve the penetration of 
anthracyclines to enhance this anti-tumour activity, and studies 
along these lines are described in the following chapters.
I
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CHAPTER 3
SURFACTANT STUDIES
One possible method of increasing the anti-tumour efficacy of 
adriamycin would be to co-administer an agent which would in 
some way improve the penetration of the cytotoxic. Optimally 
this would occur only in the target tissue (tumour) and not in 
organs of toxicity e.g. bone marrow. Surfactants are molecules 
with hydrophilic areas and hydrophobic (usually hydrocarbon) 
chains, as such they act in a similar fashion to detergents. 
Surfactants are present in many foodstuffs and are used 
commercially as emulsifiers, solubilisers, defoamers and 
detergents in the pharmaceutical, cosmetic and other industries. 
Non-ionic (or ionic) surfactants have been shown to be capable 
of altering the absorption of drugs. These effects have been 
attributed to an increase in membrane fluidity in the presence 
of the detergent. Some of the factors determining the effects 
observed include the size and polarity of the drug molecule, the 
concentration of the surfactant, the nature of the surfactant 
and drug-surfactant interactions (Florence, 1981).
The effect of the non-ionic surfactant polysorbate 80 (Tween 
80) on methotrexate absorption and distribution has been most 
extensively investigated. This non-vesicle forming surfactant 
enhances the oral bioavailability of methotrexate and resulted
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in enhanced delivery of methotrexate to the brain of treated 
animals (Azmin et al, 1982. Azmin, Stuart & Florence, 1985), the 
mechanism of this change probably involves changes in cell 
membrane structure and permeability (Kay, 1965). This could have 
therapeutic implications in the therapy of childhood leukaemia 
•with the need for penetration of drug into the 1 sanctuary site1 
of the CNS. In addition, the same surfactant has been reported 
to potentiate the anti-neoplastic effect of adriamycin (Riehm & 
Biedler, 1982), is able to restore adriamycin sensitivity in a 
cell line with in-vitro resistance to this drug (Seeber, Meshkov 
& Schmidt, 1978) and causes a reduction in peak plasma levels of 
adriamycin following co-administration in cancer patients 
(Cummings et al, 1986a).
The non-ionic polyoxyethylated lauryl ether surfactant, Brij 
30 has also been shown to enhance the cytotoxicity of adriamycin 
in-vitro (Kerr et al, 1987). This compound has not previously 
been tested in-vivo.
The toxic effects of parenterally administered surfactants 
are largely unknown. High doses can be tolerated orally 
(especially of the non-ionic surfactants),which is the most 
common route of administration (R.T.E.C.S., 1979. #JR5960000. 
Kabara,1978). Information on intravenous toxicology is scant for 
most surfactants though Tween 80 is tolerated by this route in 
rats (R.T.E.C.S., 1979. #WG2932500) and is administered in a
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dose of 400mg/m as an aid to solubility in Etoposide (VP16) as 
supplied by Bristol-Myers for use in cancer patients.
In this chapter are described experiments which attempt to 
extend some of these observations, and particularly to 
investigate the feasibility of intravenous co-administration of 
surfactants with the anthracycline cytotoxics.
MATERIALS AND METHODS
SURFACTANTS
The structure of Tween 80 (polyoxyethylene 20 sorbitan mono- 
oleate) is shown in figure 1. That of Brij 30 is given in figure
2. Both were supplied by B.D.H. Ltd, Broom Rd, Poole, Dorset, 
UK.
Surfactants I and II were the gift of the French drug company 
— L-'-Oreal in collaboration with Prof. A.T. Florence, Department of 
Pharmacy, University of Strathclyde, UK. Their available 
chemical structures are shown in figures 3 and 4 respectively.
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H0(C2H40)w  (OC2H4)xOH
CH(OC2H4)yOH
H2C<OC2H4>ZR
Sum of W,X,Y,Z is 20;
R is (C17H33)COO
Figure 1: Structure of Tween 80
/88
CH3(CH2)10CH-(OCH2CH2)4OH
Figure 2: Structure of Brij 30
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C 16H 33°(C H 2-CH-0>3H 
CH„OH
Figure 3: Structure of L'Oreal surfactant I
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C 16H 33~°~C H 2“C H 0 H ~C H 2~0 ~C H 2”C H 0 H C H 20 H
Figure 4: Structure of L'Oreal surfactant II
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IN-VIVO TOLERANCE
The surfactant solutions were diluted with 0.9% Sodium 
chloride to appropriate concentration in a final volume of 0.2 
ml for intravenous or intraperitoneal administration. Animals 
were restrained (no anaesthesia) and the surfactant injected IV 
or intraperitoneally (IP) through a sterile fine bore needle 
(25 g Microlance).
The animals used in each case were non-tumour bearing mice 
(MF1 Nu+) from our own breeding colony. The animals were fed 
standard laboratory chow and allowed water ad libitum throughout 
the experimental period. After injection the animals were 
observed for one hour and thereafter checked daily for 28 days. 
Animals exhibiting lethal toxicities were dissected post-mortem 
and the tissues fixed in formaldehyde and submitted for 
histological examination (Dr Reid, Western Infirmary, Glasgow). 
Each dose was injected into a minimum of 3 mice by each route, 
in some experiments a larger number of mice were used. A 
tolerable dose was arbitrarily defined as that which allowed at 
least 75% of animals to survive without ill effect.
IN-VITRO CYTOTOXICITY
The cell line used throughout these experiments was a human 
non-small cell lung cancer line derived in our own laboratory
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(Merry et al, 1987) known as L-DAN. Details of the growth 
conditions and the clonogenic assay used have been presented irf 
detail elsewhere (chapter 2). In addition, because the 
surfactants often cause the cells to lose their adhesion to the 
plastic surface of the culture dish, after trypsinisation the 
cultures were centrifuged at 100 G for two minutes to ensure 
that no cells were lost. In each case a dose response curve was 
constructed for adriamycin alone or adriamycin together with the 
surfactant at the chosen concentrations. All drug exposures were 
for one hour, and each assay was performed in triplicate.
RESULTS
BRIJ 30
At a concentration of 3 x 10~'* Molar Brij 30 reduced 
clonogenic survival of L-DAN by approximately 10% (Kerr et al, 
1987). An 0.2ml dose of this concentration was immediately fatal 
in 3/3 mice treated IP, and 3/3 mice treated IV. The same 
immediate fatal toxicity was exhibited at a concentration of 3 x 
10"6 M. At post-mortem dissection histological evidence of 
pulmonary oedema was found, probably due to disruption of the 
alveolar capillary membranes thus allowing major and rapid 
extravasation of extracellular fluid. After a further 10 fold
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dilution (3 x 10~^M) this toxicity was not seen. All treated 
animals surviving without apparent ill-effect to the end of the 
observation period (28 days). Unfortunately, at this 
concentration an enhancement of adriamycin cytotoxicity could no 
longer be demonstrated as shown in figure 5 (and table 10).
TWEEN 80
This agent was well tolerated by all animals treated with 
concentrations up to 0.8 Molar given IV or IP. This surfactant 
was cytotoxic in its* own right against L-DAN, even at 10”^ 
Molar clonogenic survival was consistently less than 0.3% of 
control. This high level of cytotoxicity made it impossible to 
discern any additional effect of the surfactant-drug combination 
treatment.
SURFACTANT I
—5At concentrations greater than 10 M given IV or IP to mice 
this compound produced acute fatal toxicity similar to Brij 30. 
At 10“6 M, 4/5 mice treated intravenously survived and it was 
decided to use this concentration to investigate in-vitro 
cytotoxicity. Figure 5 shows the dose response curve to 
adriamycin with and without surfactant I. It is clear that at
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Figure 5: Dose survival curve for L-Dan monolayer cells exposed
to adriamycin alone ( controls ) together with various 
surfactants. KEY: Control* stars, Brij 30= open circles, 
surfactant 1= open squares, surfactant 2= filled triangles.
!
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this non-toxic concentration there is also no enhancement of 
adriamycin cytotoxicity.
SURFACTANT II
At concentrations greater than 10”7 M given IP or IV to mice 
this compound again exhibited acute lethality similar to Brij 
30. Table 9 describes the experience of all treated mice with 
this surfactant. In each case the deaths of animals occurred 
within five minutes of injection.
TABLE 9
Dose (M) 
10~5IP
10"5IV
10”6IP
10~6IV
10~7IP
10"7IV
No. treated 
3 
3 
3 
3 
5 
5
No. of 10 day survivors 
0 
0 
1 
0 
5 
4
Thus a concentration of 10”7M was selected for in-vitro 
experiments. Figure 5 shows a dose response curve for adriamycin 
with and without surfactant II. Again this shows no enhancement
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of adriamycin cytotoxicity by this concentration of the 
surfactant.
Table 10 summarises the results of the in-vitro cytotoxicity 
assays using adriamycin in combination with the non-toxic 
concentrations of surfactants as defined above.
TABLE 10
Adriamycin Control Brij 30 Surfactant 1 Surfactant
dose (ug/ml) 3xl0"7M 10'6M »—•
 
o
i
aT
4
0 100 (5) 100 (11) 100 (6) 100 (9)
0.1 102 (10) 87 (10) 93 (4) 96 (12)
0.5 54 (7) 59 (9) 60 (5) 60 (3)
1.0 29 (8) ND 31 (3) 30 (5)
2.5 9 (2) 11 (4) 12 (3) 12 (4)
5.0 0.7 (.2) 2 (.7) 1.1 (.6) 1 (.6)
10.0 0.4 (.2) 0 (0) 0.2 (.2) 0.4 (.9)
Results expressed as mean (standard deviation) 
ND = not done.
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DISCUSSION
The increase in membrane transport observed at low 
concentrations of surfactant is attributed to the amphipathic 
nature of the surfactant and its' ability to penetrate, and thus 
disrupt, normal biomembrane structure. Many authors have 
attempted to define a strueture-function relationship for this 
effect with varying degrees of success. It appears that a 
hydrocarbon chain length of 12 is optimal in this respect 
(Walters, Duggard & Florence, 1981). This chain length is also 
associated with maximal effects on DNA synthesis and cytolysis 
in guinea-pig kidney fibroblasts in vitro, on release of 
histamine from rat peritoneal mast cells in vitro (Ferguson & 
Prottey, 1976), as anti-microbial agents (Kabara, 1978), and 
was also found to be optimal in a series of surfactants tested 
in-vitro for enhancement of anthracycline activity (Kerr et al, 
1987).
Brij 30 (a C^  compound) produced unexpected toxicity when 
administered intravenously. The timing of this toxicity and the 
histological findings suggest that this ability to disrupt 
biomembranes extents to the alveolar-capillary membrane, 
resulting in rapidly fatal pulmonary oedema. Other workers have 
shown a decrease in plasma volume after IP administration of 
Tween 80, and it is possible that this was a contributory factor 
to the toxicity observed in this study (Harrison, Cusic & 
McAfee, 1981).
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On the other hand Tween 80 was well tolerated by the 
intravenous route in the experimental animals, and in human 
subjects (Cummings et al, 1986a). It also had a profound 
cytotoxic effect in its* own right against exponential phase L- 
DAN cells in-vitro, and it proved impossible to determine if it 
had a penetration enhancing effect on adriamycin.
The other two surfactants used are compounds. At
concentrations which were tolerable to the mice neither of these 
surfactants showed any enhancement of adriamycin cytotoxicity.
Our studies, and others quoted above, suggest that not only 
is the C 2^ compound the optimum for enhancement of anthracycline 
activity, but is also highly toxic following IV administration. 
Using isolated gastric mucosal preparations a similar 
association between histological damage and the ability to 
enhance drug penetration has been demonstrated (Walters, Duggard 
& Florence, 1982). It is possible that both effects share a 
common mechanism.
One limitation of this model system is that the actual 
concentration of surfactant in the tissues was not determined. 
The concentrations in the tissues would neccesarily be less than 
those given to the whole animal (probably by at least one order 
of magnitude), and as enhancement of cytotoxicity could not be 
demonstrated at the in-vitro concentrations it is unlikely that 
an effect would be apparent in-vivo, though this was not 
formally tested.
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In addition, it is unlikely, due to whole animal variations 
in drug handling, that by simple mixing and IV co­
administration of adriamycin and surfactant both agents would 
get to the target tissue at the correct concentration and at the 
same time to allow any additive or synergistic effect. However 
it was necessary to perform these experiments as a pre-requisite 
to consideration of further use of surfactants, and they have 
helped to identify surfactants for which further study may be 
appropriate.
A possible way of alleviating the toxicity of the surfactant 
and delivering drug and surfactant at the same site and time 
would be to form vesicles from the non-ionic surfactant (similar 
to the more commonly used liposomes) which could then be loaded 
with drug. These so-called 'niosomes' are the subject of the 
following chapter.
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CHAPTER 4
STUDIES USING NON-IONIC SURFACTANT VESICLES (NIVS)
Liposomes, which are constructed of uni-lamellar or multi- 
lamellar lipid bilayers have shown some promise in drug
delivery, particularly if the target tissue is the reticulo­
endothelial (macrophage) system which actively removes 
macromolecular materials from the circulation, though problems 
still remain in tumours because of the many penetration
barriers interposed between the circulation and the target. The 
use of liposomal formulations of adriamycin (and some other
cytotoxics) is currently in Phase I - II clinical evaluation in 
a number of centres (Treat et al, 1989. Cowens et al, 1989). A 
more detailed discussion of liposomes is presented in chapter 5.
Similarly, NIVs (formerly known as ’niosomes*) are uni- or 
multi-lamellar structures composed of non-ionic surfactants, 
usually in a mixture with cholesterol. Drug can be loaded into
the aqueous phase of the vesicles during the process of
formation, or more lipophilic drugs may associate within the 
bilayers or more loosely with the surface of the vesicles
(Baillie et al, 1985).
The advantages of this approach to a ’drug carrier* is that a 
number of critical factors can be altered by variation of the 
chemical composition of the vesicles, for example; degree of 
cholesterol incorporation controls permeability (Rogerson,
Cummings & Florence, 1987), positive or negative charge of the
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vesicle may be important in targeting, size and stability may be 
altered to give a degree of control of vesicle destination. One 
theoretical advantage of NIVs over liposomes is that one may be 
delivering a penetration enhancing agent together with the drug 
payload (see previous chapter), though it remains to be proven 
if this mechanism would be active in a selective fashion at the 
target tissue (tumour), but not at the major sites of 
anthracycline toxicity (marrow, heart), which would result in an 
improvement in therapeutic ratio.
The use of surfactant micelles has been shown to enhance 
intestinal absorption (Franz & Vonderscher, 1981) and to result 
in significant changes in drug handling when used intravenously 
(Azmin et al, 1986. Cable et al, 1988). NIV lentrapment of 
adriamycin may enhance the therapeutic ratio of that drug by a 
reduction in cardiotoxicity, as implied by reduced cardiac 
uptake of this form of adriamycin whilst maintaining anti-tumour 
activity (Kerr et al, 1988).
The experiments detailed in this chapter describe our 
experience with two new formulations of NIVs, and were performed 
in collaboration with Dr.Cable and Prof.Florence, Dept, of 
Pharmacy, Strathclyde University. Some of the work has been 
previously reported in abstract form (Cable et al, 1988).
In the course of these experiments, adriamycin metabolites 
were measured as well as the parent drug, in order to establish 
if significant changes occurred in biotransformation as a 
result of changes in tissue distribution. Cummings, Merry &
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Willmott ( 1986 ) have suggested that the degree of
biotransformation may have an effect on both anti-tumour 
efficacy and the toxicity profile. However, the significance of 
serum metabolite concentrations on the therapeutic index remains 
a disputed area ( Dessypris et al, 1988).
MATERIALS AND METHODS
PREPARATION OF NIVS
Surfactants I and II were used as supplied by L ’Oreal, France 
(see previous chapter for structures). Cholesterol was obtained 
from Sigma Chemicals, Dorset, U.K. All other reagents were of 
highest purity available ( Analar or HPLC grade).
150 umol of surfactant or surfactant mixture was dissolved in 
diethyl ether or chloroform (10ml) in a round bottom flask 
(50ml), The solvent was evaporated under reduced pressure in a 
water bath at 50-60®C, using a rotary evaporator (Buchli), 
leaving the starting material as a thin film on the wall of the 
flask. The hydrating solution (2-5ml) was heated to 50^C and 
added to the round bottom flask, with gentle agitation, until no 
material remained on the wall of the flask. The flask was left 
in the water bath for a further 30 minutes, with gentle 
agitation every 10-15 minutes. The resulting niosomal suspension 
was sonicated with an MSE PG100 probe sonicator with a titanium 
probe (150Watt) for a specified time (usually 5-15 minutes) at
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15% of maximum output. In drug loaded NIVs the hydrating 
solution was 2-5 mg/ml adriamycin. In 1 empty' NIVs the hydrating 
solution consisted of 200 mM glucose( both in aqueous solution )_.
NIVs of two different chemical compositions were used in the 
following experiments. NIV I contained surfactant I (50%), 
cholesterol (25%) and a cholesteryl poly(24)oxyethylene ether 
(Solulan C-24) (25%) and had an average size of 420 nm diameter 
as determined by photon correlation spectroscopy. NIV II were 
composed of a 50:50 mixture of surfactant II and cholesterol to 
which was added 5% stearyl amine. These NIVs had a mean diameter 
of 186nm by photon correlation spectroscopy.
SEPARATION OF FREE AND ENTRAPPED ADRIAMYCIN
This was achieved by equilibrium dialysis of samples against 
200 mM glucose. A Cuprophane No.3 dialysis membrane was used, 
and dialysis performed for 48 hours at 4®C in the dark, with six 
changes of solution (6 x 800ml).
MEASUREMENT OF ENTRAPPED ADRIAMYCIN ( Rogerson et al, 1987 ).
Five ml of NIV suspension was adjusted to pH 5 to ionise the 
adriamycin, shaken for 30 seconds in 10 ml of chloroform in a 50 
ml separatory funnel, and after 5 minutes the two phases were 
separated. The upper aqueous phase contained adriamycin and the 
lower chloroform the surfactant. The aqueous phase was clarified
//
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by gentle addition of 5 ml of double distilled water, then 
collected and analysed directly. The chloroform layer was 
evaporated to dryness, avoiding heat, and was reconstituted in 
1 ml of methanol prior to immediate analysis. Cholesterol- 
containing NIVs were reconstituted in 2 ml of
chloroform:methanol (50:50 V/V) prior to analysis.
DRUG ANALYSIS
Adriamycin and its metabolite concentrations were measured in 
serum and tissues using an established reverse-phase isocratic 
high-performance liquid chromatographic technique 
developed in our laboratory (Cummings, Stuart & Caiman, 1984).
HPLC was performed using an Altex Model 100A pump amd a 
Milton Roy 'promis* autosampler programmed for a 20 ul injection 
volume (Milton Roy, Co.Clare, Ireland), and a Gilson Spectro-glo 
filter fluorimeter with narrow band interference filters at 480 
nm (excitation) and 560 nm (emission) and a 10 ul quartz micro 
flow cell (Gilson, Villiers-le-Bel, France); a Shimadzu CR-1B 
integrator (supplied by Scotlab Instrument Sales, Bellshill, 
U.K.) and a 250 mm x 4 mm internal diameter stainless steel 
column packed by ourselves with u-Bondapak C^g.
All methanol, propan-2-ol and chloroform were HPLC reagent 
grade (Fisons Scientific, Loughborough, U.K.). Orthophosphoric 
acid and all other solvents and chemicals were of analytical 
reagent grade (Analar, BDH, Poole, U.K.). Water was double­
105
distilled and deionised in a quartz glass still. The mobile
phase for the chromatographic separation of adriamycin and its
metabolites consisted of 74% 5mM (final concentration)
orthophosphoric acid, 26% propan-2-ol (pH 3.2). The mobile phase
was degassed by purging with helium for one minute. Pure
adriamycin and adriamycinol were gifts from Dr. S. Penco
(Farmitalia, Milan, Italy). 7-Deoxy-aglycones of adriamycin were
&synthesised as reported for validation of this assay (Cummings, 
Stuart & Caiman, 1984). Elution was isocratic at a flow-rate 
of 1.2 ml/min. The column was at ambient room temperature 
(normally 25^C). Quantitation of extracts was by peak area and 
was always by reference to standard calibration curves run on 
the same day. Corrections to allow for differences in the 
relative molar fluorescence of the metabolites were made to all 
metabolite concentrations according to Cummings, Stuart & Caiman 
(1984). A sample chromatogram illustrating the separation of 
metabolites and parent drug from serum is shown in figure 1.
To 200ul of mouse serum were added 100 ng daunorubicin (for 
adriamycin analysis, or adriamycin in the case of daunorubicin 
analysis) in 10 ul of methanol as an internal standard. The sera 
were then mixed with 5 volumes of chloroform - propan-2-ol (2:1) 
and whirlimixed for twenty minutes in 25 ml PTFE-lined screw 
capped test-tubes. After mixing, the samples were centrifuged at 
2000g for 15 minutes at 4^C to separate two phases. The upper 
aqueous phase was discarded by aspiration, the lower organic 
phase was transferred to clean 10 ml tapered centrifuge tubes
purity was checked by TLC and structure by mass spectrometry.
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Figure 1: Sample chromatogrijJiPP<?nsep§fatiori ^"adriamycin and 
its metabolites from human serum.
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and was evaporated in the Buchler vortex evaporator at AO^C and 
30 mm Hg of vacuum. The residue was redissolved in either 50 or 
100 ul of methanol by whirlimixing for 1 minute and 20 ul were 
injected onto the HPLC column. This extraction technique is 
capable of almost equal recovery (>77%) of adriamycin,
metabolites and daunorubicin (the internal standard).
The drug was extracted from tissues by the method of 
Cummings, Merry & Willmott (1986), which involved tissue 
homogenisation followed by treatment with AgNOg solution (33%, 
W/V) to remove adriamycin intercalated to DNA, then extraction 
with 5 volumes of Chloroform - propan-2-ol as described for 
sera.
In all samples attempts were made to measure adriamycin 
(ADR), adriamycinol 7-deoxyaglycone (7-AOL), adriamycin 7-
deoxyaglycone (7-ADR), adriamycinol (AOL) and adriamycinol 
aglycone (A0L0NE). The lower limit of detection for this assay 
is 3 ng/ml for adriamycin and 1 ng/ml for adriamycinol and the 
7-deoxyaglycones. The inter and intra-assay coefficients of 
variation for the assay are both <10%.
ANIMALS AND TUMOUR MODEL
In the NIV I experiments non-tumour bearing mice (MF1 Nu+) 
from our own breeding colony were used. For NIV II experiments
AKR mice supplied by Harlan Olac Ltd, Shaws Farm, Blackthorn,
U.K. bearing subcutaneously implanted R0S (Ridgway Osteogenic 
Sarcoma) tumour were used. In both cases the animals were fed on
standard laboratory chow, allowed water ad libitum and kept in a 
12 hour light/dark cycle throughout the duration of the 
experiments.
The ROS tumour spontaneously arose as an inguinal mass in a 
male AKM mouse in 19A8 in the laboratory of Dr. J. H. Burchenal 
at the Sloan-Kettering Institute in New York. This tumour has 
been found to respond to a wide range of drugs (including 
anthracyclines) used in the treatment of solid tumours in man. 
Furthermore it generally exhibits an orderly and reproducible 
dose response to active drugs (Laster, 1975). The tumour was 
subcutaneously implanted (taking full antiseptic precautions) as 
1mm fragments into a surgically created subcutaneous pouch on 
the right flank of lightly anaesthetised 6-8 week old mice, and 
the wound then closed by surgical skin clips. After 
approximately 12-1A days the tumours were easily palpable and 
measurable in two dimensions using calipers. The median life 
span of ROS-implanted mice is about 25-35 days.
MURINE PHARMACOKINETIC STUDIES
Groups of animals were restrained without anaesthetic and 
tail-vein injected with the following combinations: saline as 
control, adriamycin in solution at a dose of 5mg/kg (for 
formulation I experiments; for formulation II lOmg/kg was used), 
adriamycin entrapped in NIVs at a dose sufficient to deliver 5 
mg/kg or lOmg/kg respectively of the anthracycline, or 
adriamycin in solution (5 mg/kg or lOmg/kg) plus empty NIVs. In 
all experiments the same total quantity of NIVs were 
administered in the drug loaded or empty state. In
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all groups the total volume of injection was less than 0.2ml.
At specified times over the next 48 hours groups of mice 
(n=4) were sacrificed by cervical dislocation. They were 
exsanguinated from the inferior vena cava and tissues of 
interest (heart, liver, Wdneys, spleen, lungs and tumour) 
dissected out, blotted dry, and rapidly frozen in liquid 
nitrogen. The blood was centrifuged at 100 g for 2 minutes and 
the serum then removed and rapidly frozen. All samples were 
maintained at -20®C until the day of analysis.
MATHEMATICAL ANALYSIS
The area under the concentration time curve (AUC) was 
calculated by the log trapezoidal rule from time zero to the 
last measured time point (48 hours unless stated otherwise). 
Clearance was determined using the model-independent equation; 
Clearance = Dose/AUC (Gibaldi & Perrier, 1982).
Statistical comparisons were made by two way analysis of 
variance or Student’s T-test with Bonferroni correction where 
appropriate. As it was impossible to take multiple plasma 
samples from single mice, it is impossible to statistically 
compare AUCs as this parameter is derived from single samples 
from multiple animals. ^ v
TUMOUR GROWTH RESPONSES
On the 10th day after subcutaneous implantation of tumours 4 
groups of mice (n=8 for control, n=4 for experimental) were
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administered combinations of drugs as detailed above at doses 
calculated to deliver lOmg/kg of the anthracycline component. 
The resultant tumours were measured bi-dimensionally by calipers 
every 2 days thereafter until the tumour burden became 
intolerable to the animals. Tumour volume (assuming spherical 
geometry) was then calculated by the following formula:-
Volume = 4/3 If(a+b/4)^
were a is the largest diameter and b is the diameter at a 
perpendicular to a.
FLUORESCENT MICROSCOPY
Six mice with established subcutaneous ROS tumour were 
treated with NIV entrapped-adriamycin (5 mg/kg, formulation II 
only) or saline as controls. At 5 minutes, 4 hours and 24 hours 
after dosing groups of 2 animals were sacrificed and tissues of 
interest removed as detailed above. The tissues were divided 
into two; one part was rapidly frozen in liquid nitrogen, the 
other was immediately placed into a fixative composed of 80% 
propanol:20% water. The fixed samples were processed to paraffin 
wax, 5 nm sections cut, dewaxed and mounted using glycerol PSB 
mountant containing PPD (p-Phenyldiamine) which retards fading 
of fluorescence. The snap frozen samples were cut using a 
cryotome, sections were examined using a Leitz Lablux K 
Epifluorescent microscope. Photography was performed using
Ill
Kodak Ektachrome film P800/1600. The final magnification for 
the photographs was eyepiece (xlO) x objective ( x 50 water 
immersion ). I gratefully acknowledge the help of the 
Department of Pathology Southern General Hospital and Dr. 
Margaret Burgoyne in the expert processing and interpretation of 
these sections.
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RESULTS
MURINE PHARMACOKINETICS (FORMULATION I)
Peak drug levels and tissue AUC's are outlined in table 11. 
Figures 2 to 7 illustrate the concentration time profiles of 
adriamycin or its' metabolites in plasma or tissues following 
administration of adriamycin in solution (A), empty NIVs with 
adriamycin in solution (EN) or NIV entrapped adriamycin (NIO). 
Each point is the mean of at least 3 observations with 
associated standard errors.
Attempts were made to measure adriamycin (ADR), adriamycinol 
7-deoxy aglycone (7-AOL), adriamycin 7-deoxyaglycone (7-ADR), 
adriamycinol (AOL) and adriamycinol aglycone (AOLONE) in all 
samples. In tissues other than liver the metabolite 
concentrations were extremely variable, often being measurable 
in only one of 3 apparently identical samples, possibly 
reflecting inter-individual differences in drug handling between 
the mice. Such wide inter-individual variation has also been 
observed in humans, but the therapeutic significance of these 
observations are unclear ( Cummings et al, 1986 b ). These data 
are therefore not discussed in any further detail.
Figure 2 shows plasma concentration-time profiles for 
adriamycin, the peak concentration following drug-loaded NIVS 
is statistically significantly higher than adriamycin in 
solution and subsequent plasma levels decline relatively slowly !
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TABLE 11
Tissue Formulation Measured Peak +/«- S.E. (units) P* AUC**
Plasma Nio ADR 4786 496 (ng/ml) 0.013 8330
Plasma EN ADR 947 414 3919
Plasma A ADR 397 58 1283
Heart Nio ADR 5.6. 1.1 (ug/g) 0.2 54.8
Heart EN ADR 12.6 2.3 155.7
Heart A ADR 7.8 0.4 59.6
Liver Nio ADR 15.6 3.5 (ug/g) 0.17 275.3
Liver EN ADR 19.4 1.4 189.0
Liver A ADR 24.6 2.4 145.1
Kidney Nio ADR 13.1 3.5 (ug/g) 0.53 104.6
Kidney EN ADR 38.5 7.3 462.7
Kidney A ADR 33.7 27 240.6
Liver Nio 7-ADR 65.1 24.9 (ng/g) 0.01 1298
Liver EN 7-ADR 210 10 1482
Liver A 7-ADR 270 40.1 2306
Liver Nio 7-AOL 51.8 23 (ng/g) 0.006 1459
Liver EN 7-AOL 540 180 3250
Liver A 7-AOL 560 100 4038
* value from two-tailed T-test of niosomal vs. adriamycin in 
solution. ** in corresponding units x hours.
KEY: A= adriamycin in solution, EN= empty NIVs with adriamycin 
in solution, Nio= NIV entrapped adriamycin.
/■
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for this form of drug but decline exponentiallly as expected for 
adriamycin in solution or the mixture of adriamycin solution and 
empty NIVs. Since the first plasma samples were taken at 10 
minutes it is likely that the entire dose of NIV entrapped drug 
would still be intravascular, whereas for adriamycin in solution 
the drug is avidly and rapidly taken up by tissues, resulting in 
a lower measured 'peak' level. The prolonged higher plasma 
levels with NIV adriamycin could be interpreted in two ways: 
the NIVs may be stable and still in the circulation or they may 
have been deposited in tissues with drug slowly leaching out of 
the vesicles with at least a portion of the released drug 
finding its way back into the circulation i.e. a *depot'.
Figure 3 illustrates heart concentrations, and shows a 
reduction in peak levels for the NIV preparation (although not 
statistically significant, see table 1). Figure 4 shows liver 
concentrations with the expected increase in AUC for the NIV 
entrapped drug, due to reticulo-endothelial uptake of the 
vesicles. Figure 5 shows renal concentrations, with a reduction 
of 50% in AUC for the NIV preparation in comparison with 
adriamycin in solution. Figures 6 and 7 show concentrations of 
hepatic metabolites with a significant (P<0.05) reduction in 
peaks and AUCs for the NIV form of adriamycin.
I
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Figure 2: Plasma adriamycin concentration versus time 
following IV administration of formulation 1 niosomal adriamycin 
(filled circles), adriamycin in solution (open squares) or a 
mixture of empty niosomes plus adriamycin in solution (open 
circles)•
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Figure 3: Heart adriamycin concentration versus time 
following IV administration of formulation 1 niosomal adriamycin 
(filled circles), adriamycin in solution (open squares) or a 
mixture of empty niosomes plus adriamycin in solution (open 
circles).
Ti
me
 
(h
ou
rs
)
117
a on
< H
in
ftl
o
cu
in
oin
o
m
o
OJ
o
tH
in
(6/5rf) • ouoo hqv
Figure 4: Liver adriamycin concentration versus time 
following IV administration of formulation 1 niosomal adriamycin 
(filled circles), adriamycin in solution (open squares) or a 
mixture of empty niosomes plus adriamycin in solution (open 
circles).
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Figure 5: Renal adriamycin concentration versus time 
following IV administration of formulation 1 niosomal adriamycin 
(filled circles), adriamycin in solution (open squares) or a 
mixture of empty niosomes plus adriamycin in solution (open 
circles).
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Figure 6: Hepatic concentration of adriamycin 7-deoxy- 
aglycone versus time following IV administration of formulation 
1 niosomal adriamycin (filled circles), adriamycin in solution 
(open squares) or a mixture of empty niosomes plus adriamycin in 
solution (open circles).
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Figure 7: Hepatic concentration of adriamycinol 7-deoxy- 
aglycone versus time following IV administration of formulation 
1 niosomal adriamycin (filled circles), adriamycin in solution 
(open squares)or a mixture of empty niosomes plus adriamycin in 
solution (open circles).
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MURINE PHARMACOKINETICS (FORMULATION II)
Peak drug levels and tissue AUC’s are given in table 12. 
Figures 8 through 13 illustrate the concentration of adriamycin 
in various tissues following administration of NIV II as 
previously described. Each point is the mean of 4-5 observations 
with associated standard errors.
All of the adriamycin metabolites were again measured as 
described in the last section. Figures 14 to 19 illustrate 
concentration time profiles for metabolite levels in those 
tissues in which they were measurable in a consistent fashion. 
Once more occasional animals appeared to have alternative drug 
handling, but the data points shown represent the means of at 
least 3 observations.
Figure 8 shows plasma concentration-time profiles. In 
contrast to formulation I the measured ’peak* levels are very 
similar for each of the formulations, but in common with 
formulation I there are sustained relatively higher plasma 
concentrations following administration of the NIV entrapped 
drug. Figures 9 to 13 all show a similar pattern of low 
concentrations of adriamycin following NIV II administration. 
These low levels are particularly surprising in the liver and 
spleen, which are the main sites of the reticulo-endothelial 
system. Figures 14 and 16 illustrate hepatic levels of 
metabolites and are in keeping with the low levels of parent 
drug in the liver. In contrast, figures 15 and 17 show tumour
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TABLE 12
Tissue Formulation Measured Peak+/-S.E.(units) AUC(units.h)
Plasma Nio ADR 146 43 5915
Plasma EN ADR 312 94 3551
Plasma A ADR 246 20 3582
Tumour Nio ADR 1.1 0.3 24.2
Tumour EN ADR 18.2 10 263.4
Tumour A ADR 7.8 3.2 217.8
Heart Nio ADR 6.4 3.2 20.2
Heart EN ADR 19.6 1.6 222.5
Heart A ADR 17.2 1.8 155.0
Liver Nio ADR 40.7 14.3 91.4
Liver EN ADR 26.9 2.1 191.0
Liver A ADR 18.3 0.6 166.2
Spleen Nio ADR 2.0 0.75 58.8
Spleen EN ADR 14.5 3.9 564.3
Spleen A ADR 9.5 1.2 521.4
Lung Nio ADR 0.6 0.08 20.6
Lung EN ADR 24.1 2.6 430.9
Lung A ADR 20.0 1.6 331.1
Continued overleaf
Units are as given in corresponding figures 8 to 19.
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TABLE 12 (continued)
Tissue Formulation Measured Peak+/-S.E.(units) AUC(units.
Liver Nio 7-ADR 44.0 7.7 1594
Liver EN 7-ADR 351 170 2872
Liver A 7-ADR 173 30 2144
Tumour Nio 7-ADR 147 47.6 5166
Tumour EN 7-ADR 46.3 18.4 not done
Tumour A 7-ADR 0 0
Liver Nio 7-AOL 48 14.5 2075
Liver EN 7-AOL 597 204 5790
Liver A 7-AOL 682 176 6275
Tumour Nio 7-AOL 143 72 4330
Tumour EN 7-AOL 111 27 3079
Tumour A 7-AOL 272 71 4738*
Plasma Nio 7-AOL 48.4 2.5 1870
Plasma EN 7-AOL 56.8 23.6 1062*
Plasma A 7-AOL 59.0 10.0 886
Tumour Nio AOLONE 100.5 25.4 3594
Tumour EN AOLONE 470.2 45.2 5210
Tumour A AOLONE 141.0 24.0 2813*
* AUC to 24 hours only calculated.
KEY: A= adriamycin in solution, EN= empty NIVs with adriamycin 
in solution, Nio = NIV entrapped adriamycin
Units are as given in corresponding figures 8 to 19.i
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Figure 8: Plasma adriamycin concentration versus time 
following IV administration of formulation 2 niosomal adriamycin 
(closed circles), adriamycin in solution (open squares) or a 
mixture of empty formulation 2 niosomes plus adriamycin in 
solution (open circles).
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Figure 9: Tumour adriamycin concentration versus time
following IV administration of formulation 2 niosomal adriamycin 
(closed circles), adriamycin in solution (open squares) or a 
mixture of empty formulation 2 niosomes plus adriamycin in 
solution (open circles).
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Figure 10: Heart adriamycin concentration versus time 
following IV administration of formulation 2 niosomal adriamycin 
(closed circles), adriamycin in solution (open squares) or a 
mixture of empty formulation 2 niosomes plus adriamycin in 
solution (open circles).
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Figure 11: Liver adriamycin concentration versus time 
following IV administration of formulation 2 niosomal adriamycin 
(closed circles), adriamycin in solution (open squares) or a 
mixture of empty formulation 2 niosomes plus adriamycin in 
solution (open circles).
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Figure 12: Spleen adriamycin concentration versus time 
following IV administration of formulation 2 niosomal adriamycin 
(closed circles), adriamycin in solution (open squares) or a 
mixture of empty formulation 2 niosomes plus adriamycin in 
solution (open circles).
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Figure 13: Lung adriamycin concentration versus time 
following IV administration of formulation 2 niosomal adriamycin 
(closed circles), adriamycin in solution (open squares) or a 
mixture of empty formulation 2 niosomes plus adriamycin in 
solution (open circles).
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Figure 14: Liver concentration of adriamycin 7-deoxy-aglycone 
versus time following IV administration of formulation 2 
niosomal adriamycin (closed circles), adriamycin in solution 
(open squares) or a mixture of empty formulation 2 niosomes plus 
adriamycin in solution (open circles).
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Figure 15: Tumour concentration of adriamycin 7-deoxy-aglycone 
versus time following IV administration of formulation 2 
niosomal adriamycin (closed circles), adriamycin in solution 
(open squares) or a mixture of empty formulation 2 niosomes plus 
adriamycin in solution (open circles).
Ti
me
 
(h
ou
rs
)
132
o oooo oon co^in^r m cu ^
(B/du) •duod iov-Z.
Figure 16: Liver concentration of adriamycinol 7-deoxy-aglycone 
versus time following IV administration of formulation 2 
niosomal adriamycin (closed circles), adriamycin in solution 
(open squares) or a mixture of empty formulation 2 niosomes plus 
adriamycin in solution (open circles).
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Figure 17: Tumour concentration of adriamycinol 7-deoxy- 
aglycone versus time following IV administration of formulation 
2 niosomal adriamycin (closed circles), adriamycin in solution 
(open squares) or a mixture of empty formulation 2 niosomes plus 
adriamycin in solution (open circles).
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Figure 18: Plasma concentration of adriamycinol 7-deoxy- 
aglycone versus time following IV administration of formulation 
2 niosomal adriamycin (closed circles), adriamycin in solution 
(open squares) or a mixture of empty formulation 2 niosomes plus 
adriamycin in solution (open circles).
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levels of the same metabolites and indicate at least comparable 
metabolite levels following all of the tested formulations. A 
similar conclusion can be drawn from figure 19 which illustrates 
the concentration-time profile for AOLONE.
TUMOUR GROWTH RESPONSES (FORMULATION II ONLY)
Figure 20 shows the pattern of growth of ROS tumour in
control animals or those given drug treatment as stated. In the 
treated groups drug was given at day 10 following tumour
passage. There is some growth delay in the NIV entrapped
adriamycin group but ultimately all of the mice died from tumour 
burden.
No tumours arose in the mice treated with empty NIV plus
adriamycin in solution and only one tumour arose in the four
mice given adriamycin in solution confirming the sensitivity 
of this tumour to anthracyclines.
FLUORESCENT MICROSCOPY (FORMULATION II ONLY)
NIVs containing adriamycin were found to fluoresce with the 
typical orange-red fluorescence of adriamycin. The intact 
vesicles could be visualised within the blood vessels of various 
tissues soon after (5 minutes) intravenous injection of a bolus 
dose (illustration 1 and 2). At 4 hours after dosing the only 
tissue in which vesicles could be found was in the tumour
1 Fluorescent photomicrograph (magnification x500) 
of niosomes loaded with adriamycin lodged in 
hepatic sinusoids (longitudinal section) five 
minutes after intravenous bolus injection
2 Fluorescent photomicrograph (magnification x500) 
of niosomes loaded with adriamycin lodged in 
tumour vasculature five minutes after intravenous 
bolus injection
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Figure 19: Tumour concentration of adriamycinol aglycone versus 
time following IV administration of formulation 2 niosomal 
adriamycin (closed circles), adriamycin in solution (open 
squares) or a mixture of empty formulation 2 niosomes plus 
adriamycin in solution (open circles).
Ti
me
 
(h
ou
rs
)
/137
oo o r s i D i n ^ m c u - H
(ujo o t q n o )  aujniOA ueaw
Figure 20: Growth of ROS tumour in untreated ( control= open 
triangles) mice and mice treated with IV formulation 2 niosomal 
adriamycin at a dose of 10 mg/kg (filled circles).
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(illustration 3), and by 24 hours the vesicles appeared to be 
less numerous (illustration 4) with a more diffuse tissue 
fluorescence suggesting drug release into the tumour substance. 
This appearance could not be seen in any other tissue, or after 
intravenous dosing with adriamycin in solution. In fact after 
adriamycin in solution no fluorescence could be detected in the 
tumour at any of the time points.
3 Fluorescent photomicrograph (magnification x500) 
of niosomes loaded with adriamycin lodged in 
tumour vasculature four hours after intravenous 
bolus injection
4 Fluorescent photomicrograph (magnification x500) 
of niosomes loaded with adriamycin lodged in 
tumour vasculature 24 hours after intravenous 
bolus injection
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DISCUSSION
The pharmacokinetics of adriamycin in solution are well 
documented, and the data in this chapter show a general 
agreement with those in the literature (Cummings, Merry & 
Willmott, 1986). The NIVs used in these experiments are 
different from those previously reported (Kerr et al, 1988), in 
at least three important physico-chemical properties. The NIVs 
reported here are unilamellar (vs. 6 lamellae), they are 
sonicated which results in a smaller size with a tighter size 
distribution (200-400nm vs. around lOOOnm) and they are of a 
different chemical composition. All of these could have profound 
influences on vesicle stability and any targeting potential. It 
is therefore not surprising that the data obtained with 
different formulations differ in several important respects.
Ilium et al (1987), have shown that the addition of large 
molecules with hydrophilic head groups can make particulate 
carriers avoid reticulo-endothelial trapping. Thus the addition 
of solulans was made in NIV I in an attempt to mimic this 
effect. The data presented shows a prolonged maintenance of 
plasma levels of parent drug, a reduction in hepatic metabolism 
despite apparent high levels of parent drug in the liver, and a 
slight reduction in cardiac peak levels and AUC for adriamycin. 
These changes in pharmacokinetics resemble those achievable by 
prolonged infusions of the drug in solution. This approach has 
shown some therapeutic benefit, but is limited by the need for
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central venous access and expensive pumps (Legha et al, 1982). 
The use of NIV entrapped adriamycin may therefore represent a 
more practical approach to a 1slow-release1 type of preparation 
of adriamycin. The reduction in cardiac concentrations maybe of 
clinical importance since cardiotoxicity is the ultimate 
limiting factor to cumulative dosage of adriamycin in humans. 
The changes in cardiac levels seen with this preparation were 
much smaller than expected from previous studies (Kerr et al, 
1988), and prompted the change to formulation II. Additionally, 
the supply of surfactant I was discontinued due to changes in 
the manufacturing process at L*0real, France.
The reduced biotransformation to aglycones in the niosomal 
preparation may indicate an altered metabolic pathway, with 
implications both for toxicity and efficacy; though this is a 
disputed point in the literature (Cummings et al, 1986b).
In formulation II experiments there is an apparently low 
level of parent drug in all of the tissues following the 
administration of NIV II. This was unexpected and not compatible 
with the appearance of the fluorescent photomicrographs, which 
indicate accumulation of drug in the tumour. This suggested some 
artefactual inability to extract the drug from the tissues. 
Consequently, attempts were made to make the assay conditions 
more rigorous. This involved; triplicate extraction for all 
samples, maintenance of samples in contact with solvent for as 
long as 3 days, use of extremes of pH 2 - 9.5, use of different 
solvents, or the use of acid-hydrolysis. None of these proved
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able to extract the adriamycin from the samples, but samples 
passed through bond-elute columns caused a red staining of the 
column indicating the presence of adriamycin which was 
presumably firmly bound to some constituent of the NIV or 
tissue.
One would expect that intratumoural drug content (expressed 
as AUC) would bear some relationship to the cytotoxic effects of 
the drug. A gross reduction in tumour AUC is apparent with NIV 
II, which may account for the relative lack of efficacy in the 
tumour model system. The presence of an intra-tumoural 1 depot* 
of adriamycin is suggested by the fluorescent photomicrographs, 
and the low drug levels measured by HPLC are maintained for at 
least 48 hours. Bearing in mind the therapeutic benefits of 
prolonged infusions of adriamycin, it should be beneficial to 
maintain low levels of adriamycin for a prolonged period. The 
lack of anti-tumour effect for NIV II could indicate that 
although the material visible by auto-fluorecence is similar to 
native adriamycin, the drug has been inactivated. The available 
data using other NIV preparations does not support this view; 
with only pure drug released from NIVs in dialysis experiments 
(Rogerson, Cummings & Florence, 1987), and a retention of in- 
vitro and in-vivo cytotoxicity (Kerr et al, 1988). Another, 
perhaps more plausible explanation is that the rate of drug 
release from the NIVs into the tumour is crucial to optimum 
cytotoxic effect. This hypothesis could be tested by 
administration of infusions of adriamycin at different rates
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into tumour bearing animals, and if proven, the chemical nature 
of the NIVs could be altered to change permeability in order to 
optimise drug release rate.
The results of the administration of empty NIVs together 
withadriamycin in solution are interesting. In formulation II 
experiments the results are very similar to those for adriamycin 
alone. Using NIV I the results are intermediate between the drug 
in solution or entrapped within NIVs. This suggests that there 
is a loose association between the drug and the outer surface of 
the vesicles for some, but not all, types of NIVs.
The fluorescent microscopy studies show unexpected and very 
encouraging results. There appears to be a degree of passive 
targeting of NIV II to the tumour, through an initial step of 
vascular accumulation, followed by release of the drug into the 
tumour tissue. This is in keeping with the initial hypothesis 
that NIVS would be a way of delivering drug together with a 
surface active agent which would then enhance penetration of the 
drug into the tumour substance. The mechanism of this targeting 
is unclear but may relate to the defective and leaky capillary 
membranes which have been shown to be present in some tumour 
types (Warren, 1970), or to the increase in non-specific 
absorptive endocytosis reported in some tumours (Sehested et al, 
1987). It would obviously be important in further studies to try 
to retain this favourable targeting to the tumour.
The potential for change in the physico-chemical properties 
of NIVs is almost limitless. In this chapter are described two
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formulations; both of which show potential benefits over 
intravenous bolus administration of adriamycin. Nevertheless, it 
is clear that neither of our formulations is ideal. Further work 
is planned which will attempt to retain the targeting potential 
of NIVs, but have more favourable * release* characteristics, 
whilst avoiding the reticulo-endothelial accumulation which is a 
problem for all vesicular drug carriers.
The limited success achieved with this vesicular carrier 
turned our attention to other particulate carriers. Lipid based 
vesicles ( liposomes ) have been the most intensively 
investigated over the last 20 years. In the next chapter, data 
is presented on a liposomal carrier system for anthracyclines.
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CHAPTER 5
STUDIES WITH LIPID VESICLES (LIPOSOMES)
Chemotherapy has evolved as a mainly parenteral type of 
treatment. As a result most cytotoxic drugs are water soluble, 
and conversely some promising lipophilic drugs were never 
developed for intravenous use due to solubility problems.
Liposomes are vesicles which are composed of phospholipids 
and other lipids arranged in concentric bilayers or lamellae*, 
thus resembling the fmyelin figures1 formed when dried 
phospholipids are exposed to water (Stoeckenius, 1959). It was 
not until the observation in 1965 that such multilamellar 
structures could trap a range of ions and release them at 
various rates, that the potential for drug delivery of these 
vesicles was realised (Bangham, Standish & Watkins, 1965). They 
range in size from 0.05 to 5 urn in diameter and can be used as 
carriers for hydrophilic or lipophilic (Perez-Soler et al, 1988) 
drugs, which associate with the internal aqueous phase or within 
the lipid domain respectively (Kaye & Richardson, 1979). Many 
possible interactions can occur between cells and liposomes, but 
the major mechanism of internalisation appears to be by 
endocytosis (Torchillin et al, 1988. Leserman et al, 1980).
Like many other particulate materials, and despite a lipid 
composition similar to cell membranes liposomes are recognised 
as foreign and tend to concentrate in organs that are rich
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in reticulo-endothelial cells, such as the liver and spleen 
(Poste et al, 1982. Lopez-Berestein, 1984), with resulting 
adverse effects on this important host defence mechanism. This 
is the rationale to the use of liposomes to deliver antibiotics 
to the hepatic and splenic macrophages which are infected with 
intracellular organisms in some disease states, e.g. Listeriosis 
(Bakker-Woudenberg, Roerdink & Scherphof, 1988), and in the use 
of liposome entrapped rauramyl peptides to activate macrophages 
to a tumouricidal state (Creaven et al, 1989). However, this 
Kuppfer cell uptake is undesirable in tumour targeting, as a 
large proportion of the dose is removed. Attempts to inhibit 
liver uptake by pre-administration of carbon particles, empty 
liposomes, dextran sulphate or methylpalmitate have been only 
modestly successful (Proffitt et al, 1983). However, more 
recently chemical modification of liposomes has been shown to 
have a significant effect on reticulo-endothelial uptake, and it 
is now possible to design liposomes which largely avoid this 
hepato-splenic trap (Allen & Chonn, 1987. Presant et al, 1989) 
The ability of liposomes to accumulate in tissues with 
fenestrated or defective capillaries (Perez-Soler et al, 1985. 
Palmer et al, 1984) does give some reason for optimism with 
regard to targeting. Smaller vesicles can pass through the 100 
nm pores in the hepatic sinusoids to enter the space of Disse 
and interact directly with hepatocytes (Rahman et al, 1982). 
Certain tumour types are known to have defective capillaries 
(Warren, 1970), and the available data in the literature
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suggests that tumour cells show increased endocytic activity 
when compared with normal cells (Sehested et al, 1987. Trouet, 
Deprez de Campeneere & DeDuve, 1972). If this is true one would 
expect selective delivery to such tumours. The contribution of 
endocytic activity is not totally clear since liver endothelial 
cells are known to have a high endocytic rate but take up few 
liposomes in at least two independant studies (Rahman et al, 
1982).
Work done in several laboratories ( Gabizon & 
Papahadjopoulos, 1988) suggests that liposome entrapment of 
anthracyclines results in prolonged maintenance of high plasma 
levels of parent drug, similar to that seen with prolonged 
continuous infusion of the drug (Legha et al, 1982), together 
with a reduction in uptake by other tissues such as the bone 
marrow, small intestine, kidney and heart (Kaye, Boden & Ryman, 
1981. Rahman et al, 1985. Rahman et al, 1986a). The therapeutic
implications of this redistribution will depend on the tumour
cell uptake in vivo, since this would have to be at least
maintained for an improvement in therapeutic index to be
apparent. A reduction in toxicity (particularly cardiotoxicity) 
has been demonstrated in several studies of liposomal adriamycin 
(Forssen & Tokes, 1983 a and b. Rahman et al, 1986b. Gabizon, 
Meshorer & Barenholz, 1986). In most studies this is associated 
with a maintenance of anti-tumour activity (Olson et al, 1982. 
Van Hoesel et al, 1984), though in some there is enhancement of 
activity (Forssen & Tokes, 1983a. Presant et al, 1989. Dusre,
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Forst & Rahman, 1989. Gabizon et al, 1985). Interestingly, in 
the latter study this superior activity was limited to 
intrahepatic tumour, and the formulation was inactive against 
intramuscular deposits of the same tumour.
For over ten years investigations have been carried out to 
determine the therapeutic potential of liposomes as a drug 
carrier system. Early studies were mainly based on the 'passive' 
targeting aspect with drugs chosen which have therapeutic 
effects on, or mediated through the macrophages. Since the 
properties required to avoid reticulo-endothelial uptake have 
become clear, the clinical studies have taken on new impetus. 
Several groups have demonstrated tumour localisation for 
diagnostic purposes and therapeutic purposes (Presant et al, 
1989. Gabizon & Papahadjopoulos, 1988), and human phase I - II 
studies of liposomal-anthracycline preparations are underway, 
with some encouraging preliminary results (Sulkes, Barenholz & 
Gabizon, 1989. Treat et al, 1989. Cowens et al, 1989). In 
addition, recent preclinical studies suggest that liposomal 
encapsulation may be a way of circumventing adriamycin 
resistance in-vitro (Fan et al, 1989), which if confirmed in- 
vivo would be a major step forward in cancer chemotherapy.
More detailed reviews of the history and development of 
liposomes have been published in articles and book form (Kaye,
1981. Perez-Soler, 1989. Gregoriadis, 1988).
The work detailed in this chapter uses liposomes under 
commercial development by Vestar Inc. (San Dimas, California,
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USA). Consequently, certain details of formulation and 
composition cannot yet be published in full. In short, these 
liposomes are made from ultra-pure ingredients, resulting in an 
extremely stable final product, which can be lyophilised and 
therefore has a much longer shelf life. This is obviously 
advantageous for formulation and clinical applications. The 
liposomes discussed in this chapter were already loaded with 
daunorubicin on delivery, and were used immediately to minimise 
any potential drug leakage without any further preparative work.
149
MATERIALS AND METHODS
PREPARATION OF LIPOSOMES
Daunorubicin loaded liposomes were a gift from Vestar Inc. 
(650 Cliff side Dr, San Dimas, CA, USA) and used as supplied. 
Vesicle formulations containing daunorubicin consisted of 
distearoyl phosphatidylcholine and cholesterol (1:10:5 mole 
ratio). Vesicle composition and preparative procedures were 
designed to enable the usual step of removal of unincorporated 
drug from the vesicles to be eliminated ( Presant et al, 1989 ). 
The integrity of entrapped drug was verified by HPLC and thin 
layer chromatography, the final concentration of entrapped drug 
was 1.05 mg/ml. The vesicles were unilamellar, and ranged in 
size from 40 to 60 nm in diameter. They were sterilised by 
Millipore filtration at 0.22um. Physical and chemical analyses 
indicated that they are stable for at least two months at room 
temperature.
Daunorubicin was purchased from May and Baker, Dagenham, 
England; as the clinically used formulation. It was dissolved in 
0.9% Sodium chloride solution immediately prior to use.
ANIMALS AND TUMOUR MODEL
Six week old female Wistar rats were purchased from Harlan
150
Olac (Shaws Farm, Bicester, UK). They were kept in a 12 hour 
alternating light/dark cycle and allowed food and water ad 
libitum. Within one week of purchase (when mean weight = 200 
grams) a 1 cubic mm fragment of Walker 256 tumour was implanted 
into a surgically created subcutaneous pouch on the right flank 
of lightly ether anaesthetised animals, and the wound closed by 
surgical clips. Approximately 24 hours later, three groups of 10 
animals each were given tai1-vein injections of 5mg/kg of 
daunorubicin in solution, 1 ml of sterile normal saline as a 
negative control or 5mg/kg of daunorubicin entrapped in 
liposomes. The animals were then observed and resultant tumours 
measured at least twice weekly in two perpendicular diameters 
using calipers, and tumour volume calculated as in the previous 
chapter. The life-span of control animals is around 13 to 15 
days. In our experience with this tumour the percentage failure 
rate for tumour * takes* is less than 10%.
PHARMACOKINETIC STUDIES
About 5 days after tumour implantation tail-vein injections 
(as detailed above) of each formulation were administered to 
groups of 3 rats each, which were subsequently sacrificed by 
cervical dislocation at 5, 30 and 60 minutes, 3, 5, 12 and 24 
hours post-dose. The blood of each animal was immediately 
collected from the inferior vena cava. Samples were collected in 
Lithium Heparin tubes (Sherwood medical industries, County Oak
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Way, Crawley, UK) and centrifuged at lOOg for 2 minutes and the 
plasma removed and rapidly frozen, then held at -20°C until the 
day of assay. The heart, liver and tumour were dissected out of 
each animal, blotted dry and frozen in liquid nitrogen to await 
analysis.
DRUG ANALYSIS
This is described in detail in the previous chapter. The only 
difference being that in this case adriamycin was used as the 
internal standard.
MATHEMATICAL ANALYSIS
The area under the concentration time curve (AUC) was 
measured by the log trapezoidal rule from time zero to the last 
measured time point. Statistical comparisons were made by two 
way analysis of variance or Student’s T-test with Bonnferroni 
correction where appropriate. As it was impossible to take 
multiple plasma samples from the same rats, it is impossible to 
statistically compare AUCs as this parameter was derived from 
single samples from multiple animals.
The growth curves for treated and untreated animals are given 
only out to day 15 following passage, as at this time several 
animals from each group have died from their tumour burden,
thereby biasing the results towards those with smallest tumours. 
A more realistic idea of outcome is given in the ’survival* 
graph. Mann-Whitney U-test was applied in the statistical 
comparison of the growth curves.
I-
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RESULTS
PHARMACOKINETIC STUDIES
Figures 1 to 4 show the daunomycin concentration—time 
profiles for plasma, liver, heart and tumour respectively. Each 
point is the mean with associated standard errors ( n=3 for 
liposomes, n=8 for controls). In all cases the concentrations 
for liposome entrapped drug are higher over the major part of 
the time course of the experiments. Table 13 details the derived 
values of AUC. In each case the daunomycin concentration for the 
liposome group appears to fall rapidly at around 30 minutes, 
with recovery at 3 hours and thence a more orderly form of 
exponential decay is exhibited in all the tissues examined. Even 
allowing for this unusual feature the tissue AUCs are larger for 
the liposomal form of the drug ( see Table 13).
TUMOUR RESPONSE
Figure 5 shows the mean tumour volume (+/- SE) against time 
for each of the three treatment groups (n=10 each). The control 
curve is similar to that in other experiments using the same 
model (see next chapter). The free daunomycin curve shows a 
small growth delay, but this fails to reach statistical 
significance, and as shown in the survival data (figure 6) all 
tumour bearing animals in this group have died by day 17. (Two 
’no takes1 occurred in this group). The curve for liposomal
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treatment does show a statistically significant difference from 
the control curve. In this group there were no animals in which 
the tumour failed to ’take* and the downward slope after day 11 
therefore represents true tumour regressions, rather than the 
deaths of those animals with the largest tumours. In fact, this 
is the only group in which animals with palpable tumours showed 
regression and long term survival. Figure 6 details the survival 
pattern for all 3 groups until 18 days post-passage. Those 
surviving until then are still alive and tumour free at 
approximately 6 months post-passage to date.
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TABLE 13
AUC measurements for free or liposomal daunomycin 
Sample Free Liposomal
Plasma (ng/ml).h 411 692
Heart (ug/g).h 31 92
Tumour (ug/g).h 22 124
Liver (ug/g).h 25 89
x Factor
1.7 
2.9
5.8 
3.6
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Figure 1: Plasma daunomycin concentrations versus time following
IV administration of daunomycin in solution ( dots ) or
liposomal daunomycin ( open circles ).
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Figure 2: Liver daunomycin concentrations versus time following
IV administration of daunomycin in solution ( dots ) or
liposomal daunomycin ( open circles ).
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Figure 3: Heart daunomycin concentrations versus time following
IV administration of daunomycin in solution ( dots ) or
liposomal daunomycin ( open circles ).
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Figure 4: Tumour daunomycin concentrations versus time following
IV administration of daunomycin in solution ( dots ) or
liposomal daunomycin ( open circles ).
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Figure 5: Growth of subcutaneously implanted Walker 256 
carcinoma in untreated ( control= filled squares ) rats, or 
following IV administration of daunomycin in solution ( dashed 
line ) or liposomal daunomycin ( open circles ).
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Figure 6: Survival of rats bearing subcutaneously growing 
Walker 256 carcinoma without treatment ( control= filled squares 
) or following IV administration of daunomycin in solution ( 
dots ) or liposomal daunomycin ( open circles ),
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DISCUSSION
Interestingly, in all of the examined tissues the major 
portion of the liposomal concentration-time curve is above that 
for free drug. This difference is most obvious in the tissues 
rather than the plasma, as shown by the factorial changes in AUC 
detailed in table 1. No correction for enclosed blood volume 
has been made as some would suggest is necessary for this type 
of data. Great care was taken to exclude gross contamination of 
tissues with blood, and one would expect that for this source of 
experimental error to be foremost, that the plasma concentration 
profiles would show the most extreme differences.
The curious form of the concentration time profiles for 
liposomal-daunomycin is difficult to explain: it does not seem 
to have been a problem with tail-vein injection technique, nor 
with the analytical methods used. It is perhaps possible that 
this represents some form of redistribution from an initial (but 
not instantaneous) depot within a particular organ, such as the 
lung. This observation has not been made in any other animal 
test system (personal communication, E.A. Forssen) using this 
particular liposomal formulation. Further work would be required 
to elucidate this point.
The observed pharmacokinetic alterations are accompanied by a
significant increase in therapeutic activity of the liposomal
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preparation against this particular tumour model. The 
experimental protocol for this set of experiments involves 
treatment only 24 hours after tumour implantation, this is 
necessary because later treatment with anthracyclines (even at 
doses around the LD^q level) causes no tumour growth delay at 
all (data not shown). Even at this early stage histological 
studies show a developing blood supply in these small tumour 
masses, but it is possible that liposomes are being delivered in 
a non-specific way to an area with damaged vasculature following 
an operative procedure. However, all of the long term survivors 
in the liposome treatment group developed tumours at around day 
8-10, with subsequent regression of tumour from day 11 onwards.
In this model system the use of this liposome formulation has 
resulted in considerable changes in the pharmacokinetics of 
daunomycin. More drug appears to be delivered to the tumour, and 
this results in improved therapeutic responses. However it does 
appear that more drug finds its way to certain target organs for 
anthracycline toxicity (such as the heart). Two animals in the 
group scheduled for sacrifice at one hour post-treatment died 
immediately following tail-vein injection; in the control group 
no deaths were experienced. It is possible that even within the 
limited time course of these experiments overt cardiotoxicity 
was demonstrated. Thus, it remains to be demonstrated that a 
worthwhile change in therapeutic ratio has been acheived by 
liposomal entrappment of daunomycin. Unfortunately, at the time
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of writing the limited availablity of this formulation has 
prevented further therapeutic toxicity studies. Nevertheless, 
the results presented are encouraging enough to warrant further 
investigation of this type of carrier in-vivo, and further 
studies are envisaged.
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CHAPTER 6
STUDIES WITH A MACROMOLECULAR DRUG DELIVERY SYSTEM 
INTRODUCTION
A different approach to improvement in therapeutic ratio of a 
chemotherapeutic drug might be to employ a high molecular weight 
carrier. Such macromolecularised drug derivatives are expected 
to increase the efficacy of the drug through more effective 
biodistribution, retardation of metabolic degradation and 
maintenance of prolonged non-toxic levels of the drug in the 
circulation due to slow release from the carrier.
Various chemotherapeutic drugs have been shown to be more 
effective when used in association with macromolecular carriers 
such as DNA ( Cornu et al, 1974. Marks & Venditti, 1976. Trouet 
& Jolles, 1984 ); dextran ( Bernstein et al, 1978. Levi-Schaffer 
et al, 1982. Kojima et al, 1980 ); proteins ( Posnansky et al,
1982. Trouet et al, 1982 ) or polypeptides ( Kato et al, 1984. 
Zunino et al, 1984. Schechter, Wilchek & Arnon, 1987 ). In 
certain cases these drug carriers have also been claimed to 
circumvent drug resistance ( Ryser & Shen, 1980 ). Such carriers 
are non-specific in their actions, but more recently various 
groups have denmonstrated the efficacy of carrier systems based 
on tumour specific antibody-drug complexes ( Schechter et al, 
1987. Dillman et al, 1986 ).
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N-(2-hydroxypropyl)methacrylamide (HPMA) homopolymers were 
originally developed as plasma expanders, for use in emergency 
volume replacement if blood or plasma protein solutions were 
unavailable. The homopolymer is chemically inert, and exhibits 
little immunogenicity even when complexed to anthracyclines ( 
Rihova et al, 1985. Seymour et al, 1987 ), which can be a 
problem with other macromolecular carriers ( such as DNA ). 
Side-chains are readily introduced into HPMA copolymers and they 
can be used to carry a variety of prosthetic groups, such as 
drugs or targeting moieties ( Duncan et al, 1987 and 1988 ). 
Drugs containing an aliphatic amine group such as the 
anthracyclines are particularly suitable for conjugation with 
HPMA copolymers. These copolymers can be tailor made to include 
oligopeptide drug-polymer linkages that are stable in the 
bloodstream ( Rejmanova et al, 1985. Seymour et al, 1987 ), but 
can be cleaved inside the cell by lysosomal cysteine proteinases 
( Duncan et al, 1982. Rejmanova et al, 1983 ), thus releasing 
the drug into the lysosomes. The possibility of targeting these 
macromolecules has been investigated using a wide range of side- 
chain substitutions; from the simple addition of galactosamine 
residues ( Duncan et al, 1983 ) to the more complex introduction 
of tumour specific monoclonal antibodies ( Dr. L. Seymour, 
personal communication ).
HPMA copolymer anthracycline conjugates are too large and too 
hydrophilic to enter cells by passage across the cell membrane; 
the only possible mode of entry is by endocytosis. The drug
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conjugate in the endosome is then cleaved by lysosomal enzymes 
and the released drug ( like physiological degradation products, 
such as amino acids and simple lipids ) is free to make its way 
through the lysosomal membrane and to other parts of the cell to 
exert its cytotoxic effect. In the case of anthracyclines the 
most likely intracellular target is DNA; but as discussed in a 
previous chapter this may not be the only site of action for 
this class of drugs.
The binding of daunomycin to HPMA copolymers could 
theoretically change drug effect in two fundamental ways
1) Modification of pharmacokinetics
2) Delivery to specific cell populations i.e. targeting to 
tumours, with enhanced uptake through increased endocytic 
activity ( Sehested et al, 1987 ).
The data presented in this chapter supports both these 
mechanisms using HPMA copolymers as a delivery system in a rat 
tumour model. The data has been published ( Cassidy et al, 1989 
) and a reprint is bound into the back cover of this thesis.
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MATERIALS AND METHODS
SYNTHESIS OF HPMA-DAUNOMYCIN COPOLYMERS
The chemical synthesis and drug-loading of HPMA copolymers 
was performed by Dr. Ruth Duncan and co-workers at CRC Polymer- 
controlled Drug Delivery Research Group, Keele University, 
Staffordshire, UK. The synthesis involves a two step procedure, 
described in detail elsewhere ( Duncan et al, 1988 and 1989 ). 
Briefly, in the first step a reactive copolymer of HPMA with 
methacryloylated oligopeptide p-nitrophenyl ester was 
synthesised ( polymer precursor ); the second step involves drug 
binding by consecutive aminolysis ( Kopecek et al, 1985 ) to 
yield the basic structure shown in Figure 1.
In the experiments described in this chapter, daunomycin was 
bound to HPMA copolymer via a biodegradable spacer (Gly-Phe-Leu- 
Gly, POLYMER 1), or the same dose of daunomycin bound via a non- 
biodegradable linkage (Gly-Gly, POLYMER 2).
ANIMALS AND TUMOUR MODEL
Six to eight week old Wistar rats were purchased from Harlan 
Olac (Shaws Farm, Bicester, UK). They were kept in a 12 hour 
alternating light/dark cycle and allowed food and water ad 
libitum. When the mean weight was 250 grams, a 1 cubic mm
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Figure 1: Oligopolymeric structure of N-(2-hydroxypropyl) 
methacrylamide copolymers
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fragment of fresh Walker 256 tumour was implanted into a 
surgically created subcutaneous pouch on the right flank of 
lightly ether anaesthetised animals, and the wound closed by 
surgical clips. The animals were then observed and resultant 
tumours measured by the same observer at least twice weekly. Two 
perpendicular diameters were taken using calipers, and the 
tumour volume calculated using the formula given in chapter 4. 
The life-span of control animals is around 13 to 15 days. In our 
experience with this tumour the percentage failure rate for 
tumour * takes' is less than 10%.
PHARMACOKINETIC STUDIES
Five mg/kg of either free daunomycin or daunomycin bound to 
HPMA copolymer (POLYMER 1 only) was administered by tail vein 
injection to Wistar rats bearing subcutaneous implants of Walker 
256 tumour. The total volume of intravenous injection was 
approximately 0.5 ml. At various times up to 24 hours thereafter 
animals were sacrificed by cervical dislocation. Blood was 
removed from the inferior vena cava, and plasma separated by 
centrifugation. Tissues of interest were dissected out 
immediately, washed twice in ice cold saline, blotted dry and 
frozen in liquid nitrogen to await analysis. The experiments 
were carried out on two separate occasions using 2-4 animals per 
time point on each occasion.
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DRUG ANALYSIS
The determination of free daunomycin and its metabolites was 
performed using an established HPLC method (see chapter A for 
details).
The hydrophilicity of HPMA copolymer-daunomycin prevents its 
extraction into the organic phase. In addition, polymer bound 
daunomycin is only weakly fluorescent. Hence, to permit accurate 
quantitation of polymer-bound daunomycin the free drug must 
first be released from the conjugate. The glycosidic bond 
between the daunosamine ring and the aglycone moiety is 
relatively easily acid hydrolysed, releasing the free aglycone, 
A suitable hydrolysis protocol for quantitation of polymer- 
daunomycin was designed and validated by Dr, Len Seymour ( CRC 
Polymer-controlled drug delivery group; Personal communication 
). This involves exposure of samples to HCl (final concentration 
1M) at 85®C for 20 minutes, an equal volume of tris-phosphate 
buffer ( pH 9.5 ) was then added, followed by NaOH, volume
adjusted to neutralise the acid. This was performed on all 
tumour samples obtained and results in release of approximately 
100% of bound daunomycin. Subsequent extraction and processing 
was the same as for the free drug.
TUMOUR RESPONSE
Five animals in each of four groups were given (by tail vein
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injection); saline as control, 5mg/kg of daunomycin, the same 
dose of daunomycin bound to HPMA copolymer by a biodegradable 
spacer (POLYMER 1) or the same dose of daunomycin bound to HPMA 
copolymer via a non-biodegradable linkage (POLYMER 2). The 
injections were performed on the same day as subcutaneous 
implantation of 0.5 cm cubes of Walker tumour. Development of 
tumours was measured as above.
/•
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RESULTS
PHARMACOKINETIC STUDIES
The results of HPLC analyses are shown for plasma (figure 2),
liver (figure 3), tumour (figure 4) and heart (figure 5). The
results are shown as mean values +/- standard errors from two
separate experiments. In general the levels of daunomycin
metabolites parallel those of the parent drug (data not shown).
The results show a significant change in the pharmacokinetics
of the HPMA preparation. The polymer bound drug was found in the
tumour at greater concentrations than the free drug at all time 
*
points. Tumour AUC (calculated by the log trapezoidal rule) was 
increased approximately 4-fold at 24 hours. There was also a 
reduction in the cardiac concentrations with the HPMA 
preparation suggesting the possibility of an improved 
therapeutic index in this model system.
Figure 6 details the results of tumour analyses both before and 
after processing by the acid hydrolysis method to release all 
the daunomycin which initially was polymer bound. The form of 
the curves implies the formation of a depot of HPMA copolymer- 
daunomycin within the tumour, followed by a slow release of free 
daunomycin into the tumour substance.
* more than three hours post injection.
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Figure 2: Plasma daunomycin concentration versus time following
IV administration of daunomycin in solution or HPMA copolymer
bound daunomycin
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Figure 3: Liver daunomycin concentration versus time following
IV administration of daunomycin in solution ( filled diamonds )
or HPMA copolymer bound daunomycin ( open squares ).
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Figure 4: Tumour daunomycin concentration versus time following
IV administration of daunomycin in solution ( filled diamonds )
or HPMA copolymer bound daunomycin ( open squares ).
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Figure 5: Heart daunomycin concentration versus time following
IV administration of daunomycin in solution ( filled diamonds )
or HPMA copolymer bound daunomycin ( open squares )•
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Figure 6: Tumour daunomycin concentration versus time following 
IV administration of HPMA copolymer bound daunomycin ( with 
effect of addition of an acid hydrolysis step to the analytical 
methodology ). KEY: Open circles* before hydrolysis, filled 
circles* after hydrolysis.
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TUMOUR RESPONSE
Figure 7 shows the pattern of tumour growth in the four 
groups shown as the mean volumes +/- standard errors against 
time from passage. Animals were sacrificed before their tumour 
burdens became intolerable ( >6 cm in diameter ) which occurred 
from day 14 onwards. Thus in figure 8 the data are converted 
into a survival curve.
The only group showing a statistically significant growth 
delay (Mann-Whitney U test) was the group given the 
biodegradable polymer 1. In fact, 4/5 in this group were long 
term survivors (> 1 year so far), with no evidence of tumour. 
Only one other animal from any group survived and this was from 
the daunomycin group.
Although a control group using HPMA copolymer on its own has 
not been included in this series of experiments, no anti-tumour 
activity has been noted in any other system for HPMA alone.
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Figure 7: Growth of subcutaneously implanted Walker 256 
carcinoma in untreated ( control= open squares ) rats, or 
following IV administration of daunomycin in solution ( filled 
diamonds ) HPMA copolymer 1 bound daunomycin ( filled squares ) 
or HPMA copolymer 2 bound daunomycin ( open diamonds ).
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Figure 8: Survival of rats bearing subcutaneously grown Walker 
256 carcinoma without treatment, or following IV administration 
of daunomycin in solution, HPMA copolymer ( 1 ) bound daunomycin 
or HPMA copolymer ( 2 ) bound daunomycin.
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DISCUSSION
In this model system the use of HPMA copolymers to deliver 
daunomycin has resulted in a favourable modification of the 
pharmacokinetic behaviour of daunomycin. More drug reached the 
'target* tumour tissue, and less reached the myocardium, 
suggesting that cardiotoxicity of the anthracycline maybe 
reduced. This has now been confirmed independently by Yeung et 
al (1989), who found the HPMA copolymer to be about four-fold 
less toxic than the native drug. The other major site of 
toxicity for the anthracyclines is the bone marrow, causing dose 
limiting myelosuppression at around 10 days following 
administration. We did not measure marrow uptake or monitor the 
haematology of the treated animals. However, in the tumour 
response study, the animals all died of tumour burden rather 
than drug toxicity, and in the long term survivors from the 
biodegradable polymer group there was no sign of haematological 
toxicity which one would expect if the bone marrow 'dosage* had 
been substantially increased in this group.
It is reasonable to suppose that tumour drug exposure as 
reflected by AUC should correlate with response to the drug. The 
pharmacokinetic changes observed in this study could thus 
explain the increase in therapeutic effect of the HPMA copolymer 
daunomycin conjugates. However, in addition to the quantitative 
changes in drug delivery, the time course of tumour drug 
exposure has been changed, with concentrations rising throughout
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the 24 hour period in the HPMA group (see figure 4), and a slow 
release of drug from a depot of intact HPMA copolymer within the 
tumour (see figure 6). These qualitative changes in drug 
delivery may also be important for tumour response. The 
following chapter presents further data on this subject.
The effects of polymer 2 on tumour growth are worthy of 
comment. Statistically the growth rate for polymer 2 treated 
animals is not different from control. However, the impression 
is of a growth pattern which is intermediate between control and 
the active ( biodegradable ) polymer 1. This is difficult to 
explain as the drug theoretically should still be bound to HPMA 
within the lysosomes of non-biodegradable polymer 2 treated 
tumour cells. One possiblity is that even in this bound state 
the anthracycline is still able to exert a cytotoxic effect, 
perhaps by disrupting membranes as proposed by Tritton & Yee 
(1982).
The biological reason for selective delivery to tumour with 
this preparation is unclear. No specific targeting moiety was 
included in this particular formulation. The macromolecular 
nature of the HPMA copolymers means that cellular uptake must be 
through an endocytic mechanism. It is possible that at least 
some tumour types have an increased endocytic activity, 
resulting in a non-specific enhancement of uptake of 
macromolecules ( Sehested et al, 1987), though the literature is 
unclear on this subject because of major methodological problems 
in measurement of endocytosis. It has been suggested that Walker
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256 tumour contains fenestrated capillaries ( Warren, 1970 ), 
which may allow preferential 'leakage' of the polymer into the 
tumour vascular bed. The experimental protocol used in the 
tumour response study may also account for some of the 
'targeting', since the vascular damage caused by the surgical 
implantation of the tumour may have resulted in preferential 
deposition of polymer in that region. However, the 
pharmacokinetic experiments were performed in animals with 
established tumours, and similar anti-tumour responses have been 
independently observed by other groups using established tumour 
masses ( Duncan et al, 1989 )•
These encouraging preliminary results have been reproduced in 
other model systems. Clinical trials using a form of HPMA 
copolymer targeted to hepatocellular carcinoma and other forms 
of currently unresponsive tumours are planned for the near 
future under the auspices of the CRC Phase 1 trials committee.
185 
CHAPTER 7
STUDIES ON POSSIBLE MECHANISMS OF ACTION OF HPMA COPOLYMER- 
ANTHRACYCLINE CONJUGATES AND RELEVANCE TO MULTI-DRUG RESISTANCE
INTRODUCTION
As stated in the previous chapter, the use of HPMA copolymer 
carriers for daunomycin results in substantial changes in 
pharmacokinetics and an enhanced therapeutic effect when 
compared with the free drug.
These two observations could be causally related; or the 
pharmacokinetic changes may be coincidental to a more 
fundamental change in cellular drug handling resulting in 
improved effect. It is possible that the conjugation itself 
enhances the cytotoxic effect of the daunomycin by changing the 
chemical reactivity of the anthracycline. Alternatively, the 
conjugate may in some way have the effect of increasing the 
tumour penetration of daunomycin (as discussed for surfactants 
in chapters 3 and 4). Data presented in this chapter attempts to 
explore these possibilities.
In clinical oncology a major problem is the development of 
resistance to chemotherapy and subsequent relapse. Ultimately 
patients may fail to respond to any therapy, with the appearance 
of a form of multiple drug resistance. The molecular 
biochemistry and pharmacology underlying this development is
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a major area of research effort. In contrast to the clinical 
situation much of the molecular background to the development of 
in-vitro multi-drug resistance (MDR) is already well known. In 
this instance MDR is used to imply a broad pattern of cross­
resistance to 'natural product* cytotoxics, such as the vinca 
alkaloids and the anthracyclines. MDR is usually a phenomenon 
induced in immortal cell-lines by serial passage in ever 
increasing concentrations of the cytotoxic agent. One of the 
major correlates with this type of resistance is the 
overexpression of a membrane component known as P-glycoprotein. 
The current state of knowledge is that this molecule functions 
as a membrane pump, causing efflux of drug, and hence protection 
from the cytotoxic effect ( Gottesman & Pastan, 1988 ). The gene 
reponsible for the production of this protein has been 
identified and found in samples from some, but not all, 
resistant tumour types in humans ( Fojo et al, 1987 ). If one 
accepts this hypothesis one way of circumventing MDR may be to 
present the drug in a different form ( as a macromolecular 
conjugate ) or by a different route ( through the endosome- 
lysosome system ). In collaboration with Mr. S. Wedge from the 
CRC Polymer Controlled Drug Delivery Group at Keele University, 
we therefore looked at a sensitive and MDR expressing resistant 
cell-line to test these possibilities.
Finally; if the enhanced therapeutic effect of HPMA copolymer 
daunomycin conjugates is solely due to the observed changes in 
pharmacokinetics, it should be possible to reproduce the
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observed intra-tumour pharmacokinetic profile by different 
methodology and expect the same enhancement of therapeutic 
effect. This hypothesis has been tested by the crude methods of 
either increasing the intravenous dosage or using timed direct 
intra-tumoural injections of the native drug, and the results 
are further discussed in this chapter.
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MATERIALS AND METHODS
IN-VITRO CYTOTOXICITY OF HPMA COPOLYMER DAUNOMYCIN CONJUGATES 
AGAINST MONOLAYER CULTURES OF L-DAN CELLS
L-Dan cells were grown in monolayers then exposed to 
graduated concentrations of daunomycin or HPMA daunomycin 
conjugates for 1 or 24 hours in two independent sets of
experiments, A clonogenic assay was then performed on single 
cell suspensions prepared from the cultures. Each assay was 
performed in triplicate. The details of cell growth and the 
assay procedure are given in chapter 2.
IN-VITRO CYTOTOXICITY OF HPMA COPOLYMER ADRIAMYCIN CONJUGATES
AGAINST L-DAN MULTICELLULAR TUMOUR SPHEROIDS
The methods of spheroid culture and details of the
cytotoxicity assay employed are given in chapter 2. One series 
of experiments used a one hour drug exposure time. As this may 
be too short a time for penetration of the spheroid followed by 
endocytic uptake of the conjugates, a further series of 
experiments were performed with a drug exposure time of 72 
hours. In this set of experiments the drug containing medium was 
replenished every 24 hours. Each assay was performed in
triplicate with 16-20 spheroids in each treatment group.
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IN-VITRO CYTOTOXICITY OF HPMA COPOLYMER DAUNOMYCIN CONJUGATES 
AGAINST SENSITIVE AND lMDR* RESISTANT HUMAN OVARIAN CANCER CELL 
LINES
The cell-lines used in these experiments were the kind gift 
of Dr. R.F. Ozols ( National Cancer Institute, Washington, USA 
). The parental Sensitive* cell line was derived from an 
untreated patient with ovarian carcinoma. The Resistant* line 
was derived from the parental line by serial passage in 
adriamycin; it exhibits a classical MDR phenotype and has been 
shown to express elevated levels of P-glycoprotein ( Hamilton, 
Young & Ozols, 1984 ).
The cells were maintained in RPMI supplemented with bovine 
foetal calf serum 10 % and insulin 6 U/ml. The resistant line 
was routinely maintained in adriamycin but this was removed and 
cells allowed two passages prior to testing. Previous 
experiments ( data not shown ) confirm that this does not alter 
the pattern or degree of resistance of these cells. The *MTT 
assay1 as described by Carmichael et al (1979), and subsequently 
modified in our own laboratory was used ( Plumb et al, 1989 ) 
for this set of experiments, because the assay is faster than 
the standard 'clonogenic1 types. Cells are plated out at 1000 
cells/well in flat bottomed, 96 well microtitre plates (Flow, 
UK), incubated at 37^C for 48 hours and then a series of drug 
concentrations added in fresh culture medium. Fresh drug 
containing medium was added again after 24 hours incubation, to 
give a continuous drug exposure of 48 hours. Plates were then
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fed with fresh medium for each of the following five days. On 
the eighth day cells are fed with medium plus 10 mM Hepes buffer 
( which minimises differences in absorbance ) and then 50 ul of 
a 5mg/ml solution in PBS of 3-(4,5-diraethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide [MTT] is added to each well. The 
plates are then incubated for 4 hours at 37^C whilst protected 
from light by an aluminium foil wrapping. The medium is then 
removed and the insoluble formazan crystals ( formed by the 
reduction of MTT by living but not dead tumour cells ) dissolved 
in 200 ul of DMS0 (Sigma Chemicals) plus Sorensen's glycine 
buffer ( 20 ul of a 0.1 M glycine/0.1 M NaCl solution,
equilibrated to pH 10.5 with 0.1 M NaOH ). Finally the 
absorbance of light at 570nm was measured using a microtitre 
plate reader linked to a dedicated micro-computer system (Bio­
rad, UK) The assay was performed in duplicate for daunomycin or 
in triplicate for HPMA-daunomycin conjugates.
PHARMACOKINETICS AND THERAPEUTIC EFFECT OF DIRECT INTRA-TUMOURAL 
INJECTIONS OF DAUNOMYCIN
Walker 256 tumour was subcutaneously implanted into Wistar 
rats, as described in the previous chapter. Daunomycin ( May and 
Baker, Dagenham, England ) was dissolved in 0.9% Sodium chloride 
immediately prior to use. Whilst restraining the animals ( 
without anaesthetic ) an appropriate volume of drug solution was 
injected using a hypodermic syringe and 18g needle into the
191
centre of the tumour mass. Using data derived from control 
experiments on the intra-tumoural half-life of daunomycin it was 
calculated that three intratumoural doses at 4 hour intervals 
would closely simulate the kinetic profile using intravenous 
HPMA copolymer daunomycin conjugates ( see figure 4 in the 
previous chapter ). Groups of three animals each were sacrificed 
by cervical dislocation at 1, 4, 8, 12 and 24 hours following 
the first dose. The tumours were rapidly dissected out, washed 
twice in ice cold saline, and frozen in liquid nitrogen for 
subsequent analysis.
The anti-tumour effect of this regimen was assessed by serial 
tumour volume measurements and overall survival in 6 rats given 
three intratumoural doses of 1.67 mg/kg each, compared with 6 
rats given 5 mg/kg as an IV bolus.
THERAPEUTIC EFFECT OF HIGHER DOSE INTRAVENOUS DAUNOMYCIN
The improvement in tumour AUC was of the order of four-fold 
when HPMA copolymer conjugates were used in comparison to 
daunomycin alone. Therefore a group of 10 Walker tumour bearing 
rats were given 20 mg/kg daunomycin (i.e. 4 times the previously 
used dosage) as an intravenous bolus, in an attempt to improve 
the anti-tumour efficacy. This dose is above the LD^q , and as 
expected some animals died almost immediately post injection. In 
order to maintain a reasonable size group for tumour response 
estimations it was necessary to use 16 animals in total, but the
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analysis only includes those animals that survived for at least 
24 hours following dosing.
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RESULTS
IN-VITRO CYTOTOXICITY AGAINST MONOLAYER CELLS
Figure 1 shows the clonogenic survival versus daunomycin 
dosage, for a one hour drug exposure to daunomycin or HPMA 
copolymer daunomycin conjugates. The conjugated drug appears to 
have little or no cytotoxicity over the tested concentration 
range. A similar result was obtained following 24 hour drug 
exposures ( data not shown ).
IN-VITRO CYTOTOXICITY AGAINST MULTICELLULAR TUMOUR SPHEROIDS
The results of 1 hour exposure of these spheroids to 
adriamycin at various concentrations are given in chapter 2 
(figure 14), from which the growth delay data shown in figure 2 
are derived. Following one hour exposure to HPMA copolymer
adriamycin conjugates some growth delay was evident, but only at
— ^
substantially higher concentrations of adriamycin.
Exposure of spheroids for 72 hours failed to produce reliable 
data, due to technical problems. The cultures invariably became 
infected; presumably due to the repeated changes of medium and 
the necessity for an additional transfer of intact spheroids 
following the three day drug exposure. As a consequence the 
spheroids failed to return to a regrowth pattern parallel to 
control, and failed to reach 10 times their original volume,
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Figure 1: Dose survival curve for L-Dan cells exposed to free 
daunomycin ( open circles ) or HPMA-copolymer bound daunomycin 
(filled circles ) in monolayer cultures
DN
M 
C
o
n
e
. 
(u
g/
ml
)
/195
o
o
r— I
E
\
O)
3
U
c 
o
u
tr
□<
(sAea) Abisq g^M0J9
Figure 2: Derived growth delay for L-Dan spheroids exposed to
free adriamycin ( open circles ) or HPMA-copolymer bound
adriamycin ( filled circles ).
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thereby invalidating two of the assumptions implicit in the 
mathematical handling of these data. Nevertheless, it was clear 
that the conjugated form was less active than the drug alone.
IN-VITRO CYTOTOXICITY AGAINST SENSITIVE/RESISTANT CELLS
Figure 3 shows the mean optical density ( directly 
proportional to viable cell number ) +/- the standard error 
versus the log of daunomycin dosage for both cell lines. Both 
curves show the expected sigmoid pattern. Values of ID50 are 
around 0.4 ng/ml for A2780 and around 500 ng/ml for 2780AD; 
giving a relative resistance factor of ( 500/0.4 ) about 1250.
Figure 4 shows the same data for the cell lines when exposed 
to HPMA copolymer daunomycin conjugates. It is obvious that both 
curves are shifted to the right (confirming the rather poor in- 
vitro results observed with L-Dan), but that the relative 
separation of the curves remains unchanged. Values of ID50 in 
this case are approximately 200 ng/ml for A2780 and around 
200,000 ng/ml for 2780AD; giving a resistance factor of about 
1000.
If the HPMA copolymer conjugates were able to circumvent the 
resistance of 2780AD, one would expect the two curves to become 
closer (with a left hand shift in the curve for 2780AD). 
Therefore it appears that there was no modification of 
resistance in this model.
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Figure 3: Optical density versus log daunomycin concentration 
for sensitive A2780 ovarian cancer cells ( open diamonds ) and 
for resistant 2780 AD cells ( filled diamonds ) exposed to free 
daunomycin in monolayer cultures.
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Figure 4: Optical density versus log daunomycin concentration 
for sensitive A2780 ovarian cancer cells ( open diamonds ) and 
for resistant 2780 AD cells ( filled diamonds ) exposed to HPMA- 
copolymer bound daunomycin in monolayer cultures.
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INTRA-TUMOURAL INJECTIONS OF DAUNOMYCIN
The results of tumour daunomycin concentrations versus time 
are given in figure 5. Each point is the mean +/- standard error 
from three estimations. The line is a computer generated best 
fit to the data, using an in-house fitting program based on the 
least squares method (r-0.98). Although the form of the curve is 
similar to that with HPMA copolymer daunomycin, the absolute 
values are approximately 10 fold higher using direct intra­
tumour injections. This is reflected in a change in AUC 
(measured by the log trapezoidal rule) from 71 ug/g.h for the 
polymer to 1027 ug/g.h for the intra-tumoural daunomycin. 
Despite comfortably exceeding the tumour drug levels acheivable 
by the HPMA-daunomycin, this route failed to result in 
enhancement of anti-tumour effect as shown in figure 6.
HIGH DOSE DAUNOMYCIN
Assuming linearity of pharmacokinetics a four-fold increase 
in drug dosage should result in a four-fold increase in AUC. 
However, as shown in figure 7 this increase in dosage to 20 
mg/kg also failed to enhance anti-tumour efficacy in this model 
system.
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Figure 5: Tumour daunomycin concentration versus time following 
three intra-tumoural injections of 1.67 mg/kg of free daunomycin 
at 4-hourly intervals.
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Figure 6: Growth of subcutaneously implanted Walker 256 
carcinoma in rats given a single 5 mg/kg intravenous bolus 
injection of daunomycin ( stars ) or three intra-tumoural 
injections of 1.67 mg/kg of free daunomycin at 4-hourly 
intervals ( filled triangles ).
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Figure 7: Growth of subcutaneously implanted Walker 256 
carcinoma in rats given 5 mg/kg ( open squares ) or 20 mg/kg ( 
filled squares ) of free daunomycin given as a single IV 
injection.
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DISCUSSION
The relative lack of in-vitro activity for HPMA copolymer 
daunomycin conjugates was not unexpected, and similar results 
have been obtained with other macromolecular carriers. It is 
clear from the spheroid experiments that cytotoxicity is present 
in-vitro if sufficient dbsages are employed.
The bond between the polymer backbone and the daunomycin can 
only be cleaved by lysosomal enzymes, which requires that the 
conjugates are first internalised by endocytosis. The diffusion 
of these large molecules into a multicellular spheroid would be 
limited, and slow. It is not surprising that no growth delay was 
observed after a short drug exposure. In the previous chapter, 
the slight anti-tumour effect of a non-biodegradable polymer 
might have been a result of membrane activity of bound 
daunomycin ( Tritton & Yee, 1982 ). The data in this chapter 
would seem to negate this hypothesis.
Other drug carriers have been shown to overcome drug 
resistance to methotrexate when the resistance was due to a 
transport defect ( Ryser & Shen, 1980 ). It appears that the MDR 
phenotype expressed by 2780AD cells cannot be altered by the use 
of HPMA copolymer anthracycline conjugates. However, it should 
be noted that the degree of resistance exhibited by these cell- 
lines is much greater than can be demonstrated in patient 
derived material (where a resistance factor of less than 10 is
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the norm). This extreme degree of resistance may have 
overwhelmed any more subtle modifications which may have been 
made by this form of lysosomotropic treatment. Therefore, it is 
intended to repeat this series of experiments using cell lines 
with less extreme resistance characteristics.
It would be possible to explain the increase in therapeutic 
efficacy of HPMA-daunomycin purely in terms of beneficial 
changes in pharmacokinetic handling, as demonstrated in chapter 
6. However, despite reproducing the form, and exceeding the 
quantitative changes, by direct intra-tumoural injection of 
drug, we were unable to reproduce the therapeutic effect. The 
measurement of tumour drug levels is a crude estimation of drug 
delivery, as it does not take account of the cellular 
distribution of the drug. It is possible that the specific 
delivery of drug into the lysosomes is the important factor, and 
this is unlikely to be the normal route of intracellular entry 
of native anthracyclines.
In conclusion, in vitro studies to date indicate that changes 
in whole tissue penetration are not relevant, but the effect of 
HPMA copolymer presumably is explained by enhanced cellular 
uptake via the lysosomal pathway. Further studies using other 
tumour models, i.e. human tumour xenografts, are necessary, 
prior to clinical trials of this very promising avenue for drug 
delivery.
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CHAPTER 8
CONCLUDING REMARKS AND FUTURE PROSPECTS
It is clear that the efficacy, and at least by implication 
the therapeutic index, of existing anthracyclines can be 
improved by the use of various synthetic drug carrier systems.
The simplistic approach of co-administration of a penetration 
enhancing agent such as a surfactant was found to be unhelpful, 
but perhaps this may be more logically applied to the setting 
of regional chemotherapy where high local concentrations can be 
achieved with simultaneous high drug concentrations in the 
vicinity of the tumour. Penetration enhancers may yet find a 
role in intraperitoneal therapy or in isolated limb perfusion 
techniques.
These remarks may also apply to those carriers which aim to 
improve whole tumour penetration such as non-ionic surfactant 
vesicles which could, for example, be administered 
intraperitoneally to form a 1depot* of drug. The demonstration 
of a degree of tumour targeting using NIVs was a promising, if 
somewhat unexpected observation. Perhaps the physico-chemical 
properties of the NIVs are more important for tumour targeting 
than the constituent molecules i.e. the nature of the vesicle 
forming lipid may not be critical. Further work is necessary to 
define the optimal chemical and physical properties of NIVs, and
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in the light of the problems encountered with inactivation of 
entrapped drug, this should be a particular focus.
Other systemic carriers of more potential are those which may 
improve therapeutic index by reducing uptake in normal tissue 
and / or improving uptake in tumour. This seems to be the case 
for both liposomes and HPMA copolymer conjugates. One could 
hypothesise that a common mechanism involving increased tumour 
endocytosis may be responsible for the results obtained in both 
cases. It is possible that this increase in endocytosis is a 
peculiarity of certain animal tumour models, so it would be 
important in future studies to include human tumour xenografts 
to exclude this possibility and confirm the results found here. 
Possibly the constituents or some physico-chemical property of 
the carrier actually causes the increase in endocytosis, such as 
when macrophages encounter particulate matter. In addition, 
there appears to be a change in the pharmacokinetics of the 
anthracyclines using these carriers to a more 'slow release' 
preparation. This may also be involved in the improved efficacy 
as can be demonstrated by prolonged intravenous infusion of 
anthracyclines, so even if human tumours do not exhibit 
increased endocytosis, all is not lost. However, the studies on 
the mechanism of action of HPMA copolymer conjugates suggest 
that this is not a complete explanation of the benefits of at 
least that carrier system.
The diverse biochemical and biophysical properties of drug 
carriers means that the possible changes in size, chemistry,
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charge, etc. are almost endless. Future development work 
particularly with an emphasis on improved tumour targeting is 
justified. The history of liposome development illustrates the 
likey path for drug carriers; initial optimism, followed by 
scepticism and a realisation of the potential problems, and 
finally a concerted research effort to define a clinical role.
The liposomes used in this work are currently in early 
clinical trials with interesting effects, such as a diminution 
in alopecia and bone marrow toxicity; the results in terms of 
therapeutic efficacy are eagerly awaited. HPMA copolymers are at 
an earlier stage of development but plans exist to perform 
clinical trials, probably involving patients with Hepatoma 
because some formulations show extremely efficient targeting to 
hepatocytes.
/■
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INTRODUCTION:
Many drug delivery or 'targeting' systems have been developed with differing degrees of 
success in improving therapeutic efficacy. Polymeric drug carriers based on water soluble 
non-immunogenic copolymers of N-(2-hydroxypropyl.) methacrylamide [HPMA] have been developed 
in recent years by Duncan et al [1,2]. This group have shown that 1t is possible to 
covalently bind drugs to these carriers so that the polymer-drug linkage Is stable 1n the 
bloodstream [3,4,5], but can be cleaved inside the cell by lysosomal cysteine proteinases 
[6,7]. Theoretically this could change drug effect in two fundamental ways:-
1) Modification of pharmacokinetics.
2) Delivery to specific cell populations I.e. 'targeting' to tumours (with enhanced 
uptake through increased endocytic activity [8]).
We present data to support both of these mechanisms using HPMA copolymers as a delivery 
system (for daunomycin) in a rat tumour model.
MATERIALS AND METHODS:
SYNTHESIS:
The HPMA copolymer-daunomycin conjugates were synthesised using a two step procedure 
[1,2]. In the first step a reactive copolymer of HPMA with methacryloylated oligopeptide 
p-nitrophenyl ester was synthesised (polymer precursor). To the latter, daunomycin was 
bound by ami nolysis.
PHARMACOKINETICS,
Five mg/kg of either free daunomycin or daunomycin bound to HPMA coplymer (polymer 1 
only) was administered by tall vein Injection to Wlstar rats bearing subcutaneous Implants 
of Walker 256 tumour. At various times up to 24 hours thereafter animals were sacrificed by 
cervical dislocation. Blood was removed and plasma separated by centrifugation. Tissues of 
Interest were dissected out Immediately, blotted dry and frozen In liquid nitrogen to await 
analysis. The determination of free daunomycin (and its metabolites) was performed using an 
established HPLC method [9], The experiment was carried out on two separate occasions using 
2-4 animals per time point on each occasion.
Footnote; Abbreviations used Gly « glycine
Phe « phenylalanine 
Leu « leucine
AUC * area under concentratlon-time curve 
HPMA « N-(2-hydroxpropyl)methacrylamide
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TUMOUR RESPONSE,
Five animals In each of four groups were given (by tail vein Injection); saline as 
control, 5mg/kg of free daunomycin, the same dose of daunomycin bound to HPMA copolymer by 
a biodegradable spacer (Gly-Phe-Leu-Gly,POLYMER 1) or the same dose of daunomycin bound to 
HPMA copolymer via a non-b1odegradable linkage (Gly-Gly,POLYMER 2). The Injections were 
performed on the same day as subcutaneous implantation of 0.5 cm3 cubes of Walker tumour. 
Subsequent tumour growth was measured bl-dimensionally by calipers every 2-3 days and the 
measurements converted to a volume assuming spherical geometry.
RESULTS:
PHARMACOKINETICS,
The results of HPLC analyses are shown for plasma (FIG. 1a), U v e r  (FIG. 1b), tumour 
(FIG. 1c) and heart (FIG. 1d). The results are shown as mean values +/- standard errors 
from two separate experiments. In general levels of daunomycin metabolites parallel those 
of the parent drug (data not shown).
The results show a significant change 1n the pharmacokinetics of the HPMA preparation. 
The polymer-bound drug was found 1n the tumour at greater concentration than the free drug 
at all time points. Tumour AUC was Increased approximately 4-fold at 24 hours. There was 
also a reduction 1n the cardiac concentrations with the HPMA preparation suggesting the 
possibility of an Improved therapeutic Index in this model system.
TUMOUR RESPONSE,
FIG. 2a shows the pattern of tumour growth in the four groups shown as the mean volumes 
+/- standard errors against time from passage. Animals were sacrificed before their tumour 
burdens became Intolerable ( >6 cm 1n diameter } which occurred from day 14 onwards. Thus 
in FIG. 2b the data are shown converted Into a 'survival curve'.
The only group showing a statistically significant growth delay (Mann-Wh1tney U test) 
was the group given the biodegradable polymer 1. In fact 4/5 animals 1n this group were 
long terra survivors (>120 days so far), with no evidence of tumour. Only one other animal 
from any group survived and this was in the free daunomycin group.
DISCUSSION:
In this model system the use of HPMA copolymers to deliver daunomycin has resulted 1n a 
favourable modification of the pharmacokinetic behaviour of daunomycin. More drug reached 
the 'target' tumour tissue, and less reached the myocardium, suggesting that cardiotoxicity 
of the anthracycl 1 ne may be reduced. The other major site of toxicity for the 
anthracycl1nes 1s the bone marrow, causing dose limiting myelosuppreslon [4]. We did not 
measure marrow uptake or monitor the haematology of the treated animals. However, In the 
response study,the control animals all died of tumour burden rather than drug toxicity, 
and in the long-term survivors from the blodegradeable polymer group there was no sign of 
haematological toxicity which one would expect 1f the bone marrow 'dosage' had been 
substantially Increased. These pharmacokinetic changes have been shown to result in 
enhanced anti-tumour activity in this model system. It 1s interesting that the non- 
blodegradable polymer group also seemed to show some growth delay though this did not 
reach statistical significance.
The biological reason for selective delivery to tumour with this preparation 1s 
unclear. The macromolecular nature of the HPMA copolymers means that cellular uptake must 
be through an endocytlc mechanism. It 1s possible that tumour cel.ls have Increased 
endocytic activity resulting 1n enhanced uptake of macromolecules [8], It has been 
suggested that Walker 256 tumour contains fenestrated capillaries [10] which may allow 
preferential 'leakage' of the polymer In the tumour vascular bed. These preliminary
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results are encouraging, but need to be reproduced in other model systems. Clinical trials 
using a form of HPMA copolymer targeted to hepatocellular carcinoma are planned for the 
near future.
REFERENCES:
1) Duncan R, Kopeckova^Rejmanova^P, Strohalm 0, Hume 1, Cable HC, Pohl 3, Lloyd 3B, Kopecek 
3. Anti cancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 1. Evaluation 
of daunomycin and puromycin conjugates 1n vitro. Br 3 Cancer 55: 165-174, 1987.
2) Duncan R, Kopeckova'’ P, Strohalm 3, Hume IC, Lloyd 3B, KopScek 3. Anticancer agents 
coupled to N-(2-hydroxypropylJmethacrylamide copolymers. 11. Evaluation of daunomycin 
conjugates in vivo against L1210 leukaemia. Br 3 Cancer 57: 147-156, 1988.
3) Rejmanova^ P, Kopecek 3, Duncan R, Lloyd 3B. Stabllty in rat plasma and serum of 
lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide 
copolymers. Biomaterials 6: 45-48, 1985.
4) Rihova B, lllbrich, K, Strohalm 3, Vetvlcka V, Bllej M, Duncan R, Kopecek 3. 
Biocompatability of N-(2-hydroxypropylJmethacrylamide copolymers containing adriamycin. 
Biomaterials, in press, 1988.
5) Seymour LW, Duncan R, Strohalm 3, Kopecek 3. Effect of molecular weight of N-(2- 
hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after 
subcutaneous, intraperitoneal, and Intravenous administration to rats. 3ournal of 
Biomedical Materials Research 21: 1341-1358, 1987.
6) Duncan R, Cable HC, Lloyd 3B, Rejmanova^P, Kopecek 3. Degradation of side-chains of N- 
(2-hydroxypropyl)methacrylaam1de copolymers by lysosomal thlol-proteinases. Blosci. Rep. 
2: 1041-1046, 1982.
7) RejmanovrP, Kopecek 3, Pohl 3, Baudys M, Kostka V. Polymers containing enzymatically 
degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl) 
methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184: 2009-2020, 
1983.
8) Sehested M, Skovsgaard T, Van Deurs B, Winther-Nlelsen H. Increase In nonspecific 
adsorptive endocytosls in Anthracycline and Vinca alkaloid-resistant Erlich ascites tumour 
cell lines. 3.N.C.I. 78(1): 171-177, 1987.
9) Cummings 3, Merry S, Willmott N. Disposition kinetics of Adriamycin, Adriamyclnol and 
their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing Ridgway Osteogenic 
Sarcoma (R0S). Eur 3 Cancer Clin Oncol 22(4):451-460,1986.
10) Warren BA. The ultrastructure of the m1croc1rculat1on of the advancing edge of Walker 
256 carcinoma. Microvasc Res 2: 443-453, 1970.
D
au
no
m
yc
in
 
D
au
no
m
yc
in
 
co
nc
en
tr
at
io
n 
(u
g/
g)
 
co
nc
en
tr
at
io
n 
(n
g/
m
l)
878
I
Rapid communications
Fig. 1a
160 - 
140 - 
120 - 
100 - 
80 - 
60 
40 - 
20 -
r?
k
Not detected (or polymer 1
«>• W
H5 °3 C • OO u
H i-
8 12 16 20 24
Time (hours)
Fig. 1b
10
1
0 84 12 16 20 24
Time (hours)
Fig. 1c Fig. 1d
5
4
3
2
1
. . .
0
0 84 12 16 20 24
« •>» W
i * IO o
10
1
8 12 16 20 240 4
Time (hours) Time (hours)
Figure 1. Free daunomycin levels by HPLC analysis in samples from (a) plasma, 
(b) liver, (c) tumour, (d) heart. ••••»«••!• Free
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polymer 1 polymer 2 (■•-•-), following subcutaneous passage of
Walker tumour.
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